Novartis Investor Relations

Q4 2020 Results Investor presentation January 26, 2021

Updated from January 26 to address clerical error on slide 126 and 127 Disclaimer

This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding the impact of the COVID-19 pandemic on certain therapeutic areas including dermatology, ophthalmology and the Sandoz retail business, and on drug development operations; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group’s liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding our not-for-profit portfolio of 15 medicines from the Sandoz division for symptomatic treatment of COVID-19 and our collaboration with Molecular Partners to develop, manufacture and commercialize potential medicines for the prevention and treatment of COVID-19. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: liquidity or cash flow disruptions affecting our ability to meet our ongoing financial obligations and to support our ongoing business activities; the impact of the COVID-19 pandemic on enrollment in, initiation and completion of our clinical trials in the future, and research and development timelines; the impact of a partial or complete failure of the return to normal global healthcare systems including prescription dynamics by mid 2021; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this presentation; the potential that the strategic benefits, synergies or opportunities expected from the transactions described, including BeiGene, may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, investigations or disputes; our performance on environmental, social and governance measures; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Enbrel® is a registered trademark of Amgen, Inc. Humira® and Skyrizi™ are registered trademarks of Abbvie Inc. Siliq® is a registered trademark Valeant Pharmaceuticals International, Inc. Taltz® is a registered trademark of Eli Lilly and Company. Stelara®, Tremfya® and Simponi® are registered trademarks of Janssen Biotech, Inc. Cimzia® is a registered trademark of UCB Group of Companies.

2 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Participants

Vas Narasimhan John Tsai Chief Executive Officer Head of Global Drug Development and CMO

Harry Kirsch Richard Saynor Chief Financial Officer CEO, Sandoz

Marie-France Tschudin Shannon Thyme Klinger President, Novartis Pharmaceuticals Chief Legal Officer

Susanne Schaffert President, Novartis Oncology

3 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Vas Narasimhan Chief Executive Officer

Company overview

4 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation We are transforming Novartis...

Strategy set out in 2018...... is transforming Novartis

Our focus Our five priorities 100% focused as a medicines company Focus our Unleash the Deliver company power of our transformative and capital people innovation Leading pipeline, with 4 advanced therapy platforms

Achieved USD 2bn cost savings over 2017-2020 Accelerate Embrace Go big certain operational on data geographies excellence and digital Establishing a leading digital and data science platform

Improving ESG scores, sector-leading across 4 key indices Strengthen Build trust our core with society Record-high engagement score

5 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation ...while delivering strong operational performance

1 3 1 Innovative Medicines Net sales +5% CAGR Core OpInc +10% CAGR 3 Continuing operations2, USD bn core margin up to 35%

2017 2018 2019 2020 2017 2018 2019 2020 2017 2018 2019 2020

48.7 35.0% 47.4 15.4 14.1 33.5% 44.8 32.0% 42.3 12.6 11.7 31.0%

1. CAGR % 2017-20 in USD 2. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions 3. Constant currencies (cc) and core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report

6 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Q4 sales growth and margin expansion driven by strong performance from key growth drivers

Operational performance Key growth driver sales Q4 2020 Key growth drivers and launches, Growth 1 Continuing operations , % cc vs. PY Sales Growth vs. PY vs. PY as % of Innovative Medicines sales USD mn USD mn cc

® 716 198 35% 52% Adakveo Beovu® Q4 2020 FY 2020 1,109 13% 144 Mayzent® 43% Piqray® Net 3% 471 91 23% sales Xiidra® 376 83 24% Lutathera® 34% 1% 254 68 33% Kymriah®

® 240 62 32% 28% Kisqali Ilaris® 408 52 13% Zolgensma® 2 Core 13% 141 45 42% Jakavi® OpInc Tafinlar+Mekinist® 57 40 nm Promacta® 34 33 nm Entresto® Cosentyx® 335 32 8% Q4 Q4 Q4 Q4 3 2% 2017 2018 2019 2020 Other 184 29 18% 3. Includes Tasigna®, Xolair®, Aimovig®, Tabrecta ®, Kesimpta®, nm – not meaningful Luxturna® , Enerzair ® and Atectura®

1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions 2. Core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report

7 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Zolgensma® sales of USD 920m in first full year since launch, now registered in 37 countries

Performance highlights Sales evolution USD m . Delivered significant growth in 2020 despite COVID-19 delaying new starts and switches; impact expected to continue through H1 2021 . Treatment of choice for newly diagnosed patients 291 . >800 patients have received Zolgensma®; now registered in 37 countries 254 . Shift toward broader labeling (e.g. EU, Canada) and use globally - In EU, 15% of patients >2 years old and 2% over 13.5kg 205 169 . Access pathways in 9 EU countries (~25% of the population) 170 148 Growth opportunities in existing indications 44 100 . Approvals expected H1 2021: Switzerland, Australia, Argentina, South Korea . Formal reimbursement expected in 15 countries by 2022 (.e.g UK, Spain, Canada, Brazil, Argentina) . Expected increase in newborn screening: >80% in US and 20% in EU by end 20211 126 105 122 106 Clinical and pipeline . Confirmatory data in 2021: cumulative IV safety, final STR1VE-EU & STR1VE-US results Q1’20 Q2’20 Q3’20 Q4’20 . IT partial clinical hold: preclinical studies on track; FDA recommends a pivotal confirmatory study to be initiated after partial clinical hold is lifted Ex-US US . 10+ early-stage programs with two INDs planned in 2021

1. Newborn screening implementation may be impacted by COVID-related delays

8 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation China: Rich pipeline, NRDL successes, expected to double sales by 2024 Second fastest growing pharmaceutical multinational company in China in 2020

Sales . China net sales grew +16% despite COVID-19 impact 1 Continuing operations , USD bn, % cc . Key growth drivers continued momentum, FY sales growth YoY: Entresto®, Cosentyx®, Oncology strategic brands2 +16% 2.6 . NRDL achievements in 2020: - Successfully listed: Cosentyx® (PsO & AS), Gilenya®, Mayzent®, 2.2 Tafinlar® & Mekinist®3 - Renewed listing: Tasigna®, Votrient®, Sandostatin® LAR, Zykadia®

. Rich pipeline: - 2020 NDA approvals: Cosentyx® AS, Mayzent®, Pataday®, Tafinlar®+Mekinist® adj, Zykadia® 1L - 7 approvals expected in 2021 (NDA submitted in 2020) - Kesimpta® granted China priority review, TQJ230 obtained 1st BTD - New launches planned by 2023: Kisqali®, ACZ885 - New indications by 2023: Afinitor® (ER+ 2/3L BC), Tafinlar®+Mekinist® 2019 FY 2020 FY (BRAF+ NSCLC), Revolade® (SAA 2L/1L)

BTD – break through therapy designation 1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions 2. Oncology strategic brands include: Strategic brands: Revolade®/ Jakavi®/ Tasigna®/ Exjade®/ Votrient®/ Sandostatin® LAR/ Zykadia®/ Tafinlar®+Mekinist® 3. Azarga® and Simbrinza® were also successfully listed in NRDL

9 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Sandoz sales met guidance with significant margin growth, despite pandemic impact

Sales stable, core margin Key 2020 performance drivers Driving growth increased by +3.3%pts in 2020 1 (vs. PY, in cc) Biopharmaceuticals growth Biosimilars +19%, increasing share in . 15+ pipeline assets, many entering clinical maturing European markets phase soon Q4 2020 FY 2020 . Sales of up to USD 3.5bn expected by 2025 Retail decline Net sales driven by COVID-19 and US Small molecules 0% oral solids . High LoE coverage (EU: >80%, US: >50%) 0% with approximately 40 US first-to-files until Margin increase from 2024 product mix, productivity, Core OpInc favorable price effects; 15% reduced spend Driving margin (mid-to-high 20s in mid-to long term)

3% . Manufacturing optimization . Product mix from higher biosimilar share . Operational excellence including use of digital Core 20.8% 24.2% margin: +3.3%pts

1. Biopharmaceuticals include biosimilars, biopharmaceutical contract manufacturing and Glatopa®

10 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Novartis focused on overcoming COVID-19 challenges

Select examples

Dermatology market declines with COVID-19 Key areas impacted in 2020 expected to PsO market weekly patient visits Jan-Aug 2020 PsO market weekly NBRx Jan-Aug 2020 continue through H1 2021 25 4.0

20 3.0 Dynamic segment of . Several therapeutic areas, 15 2.0 market (new/switch particularly dermatology and

10 Thousands patients): less patient ophthalmology 1.0 5 traffic, less F2F

Visit Visit Volume (thousands) . New launches 0 0.0 physician access ® ® Jan Mar May Aug Oct Dec Jan Mar May Aug Oct Dec (e.g. Kesimpta , Mayzent ) Sources: IQVIA Visits Data. IQVIA National Prescription Audit for Dermatology . Advanced breast cancer (CDK4/6 market and Piqray®) Oncology market declines with COVID-19 Biopsy and surgery rates CDK4/6 market NBRx ® 120 Hospital initiation (lab . Kymriah -20% work, diagnostics); 100 . Lutathera® immuno-suppression 80 concerns . Zolgensma® 60

40

20 Breast Lung Melanoma Lower demand . Sandoz Retail 0 Pre- Mar Apr May Jun Jul Aug Sep Oct Pre-COVID baseline Sep’20-Nov’20 Avg. and anti-infectives COVID Q3’19-Q1’20 Avg.

Source: IQVIA APLD, Novartis Analysis Source: IQVIA projection

11 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Key innovation milestones in Q4

® Positive FDA Leqvio CRL update Approvals AdComm Opinion In-licensing deals . CRL due to unresolved facility Tislelizumab inspection-related conditions at BeiGene EU for HFpEF (anti-PD-1) 3rd party manufacturer in Europe2 Hyperlipidemia . No concerns raised in CRL Anti-COVID-19 Molecular regarding efficacy or safety EU for Sickle cell DARPins Partners of Leqvio® disease Positive readout . Response to CRL based on DME1 3rd party readiness to be US for CRSwNP submitted Q2-Q3 2021 . Need for FDA inspection LNP023 (iptacopan): FDA breakthrough designation (PNH), Rare Pediatric Disease Designation (C3G) under discretion of FDA QGE031 (ligelizumab): FDA breakthrough designation (CSU) granted in December 2020 . Concurrently working on technology transfer to add Novartis own facility

All abbreviations on slide 144. CRSwNP – Severe chronic rhinosinusitis with nasal polyps. 1. Ph3 KESTREL study 2. Third party site originally scheduled for inspection May 2020; underwent paper based review due to pandemic.

12 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation 2021 catalysts maintaining long-term momentum

Potential catalysts Selected examples Major approvals Kesimpta® (EU/JP) Entresto® (US) Cosentyx® (US/JP/CN) RMS HFpEF Pediatric psoriasis Major submissions1 Alpelisib (BYL719) Asciminib (ABL001) Jakavi® PROS CML Acute and chronic GvHD

Beovu® Leqvio® (US)2 Kymriah® DME Hyperlipidemia FL Major readouts 177Lu-PSMA-617 Sabatolimab (MBG453) Canakinumab (ACZ885)3 mCRPC MDS NSCLC 1L + 2L Enabling submission 2021 Kymriah® Entresto® r/r DLBCL 1st relapse Post-AMI

Ligelizumab (QGE031)4 Cosentyx® Enabling submission 2022 CSU HS

Iptacopan (LNP023) Kisqali® Others IgAN, C3G (Ph2) Breast cancer (MONALEESA-2 OS) Pivotal study starts Iptacopan (LNP023) Ligelizumab (QGE031) 177Lu-PSMA-617 IgAN, C3G, aHUS Food allergy, CINDU pre-taxane

1. First submission in any market. 2. Novartis received a CRL from the FDA due to unresolved facility inspection-related conditions at a third-party manufacturing facility in Europe. FDA has not raised any concerns related to the efficacy or safety of inclisiran. Response to CRL planned to be submitted Q2 - Q3 2021. 3. Depending on timing of final read-out submission may move to early 2022 4. Q4/2021-Q1/2022 potential COVID impact

13 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Moving forward a breadth of assets to drive long-term growth

Selected opportunities: selection of expected 2021 milestones and additional indications Lifecycle management Pharmaceuticals Oncology

Post-AMI: PARADISE Iptacopan IgAN, C3G: Ph2 readout H1 2021 Canakinumab NSCLC 1L/2L: CANOPY-1/2 Ph3 readout H1 2021 Ph3 readout H1/2 2021 Entresto® (LNP023) (ACZ885) aHUS: Ph3 start. PNH, iMN HFpEF: FDA action date Q1 2021 NSCLC adjuvant Iscalimab 177 HS: SUNRISE, SUNSHINE Sjögren's, kidney Tx, liver Tx Lu-PSMA-617 mCRPC 3L: (CFZ533) Ph3 readout H2 2021 VISION Ph3 readout H1 2021 Cosentyx® L. Planus, Peds PsO, jPsA/ER, Ligelizumab CSU: PEARL 1, 2 mCRPC pre-taxane: GCA, lupus nephritis (QGE031) Ph3 readout H2 2021 Ph3 start H1 2021 Sabatolimab HR-MDS: STIMULUS ® aBC: MONALEESA-2 OS CINDU, food allergy Kisqali (MBG453) Ph2 readout H2 2021 readout H2 2021 Ph3 start H2 2021 PROS: submission H2 2021 AML Pelacarsen BYL719 CVRR-Lp(a) TNBC, ovarian cancer, HER2+ (TQJ230) TNO155 Solid tumors, multiple aBC, HNSCC 2/3L combinations being explored Branaplam HD: Ph2b start H2 2021 in on-going trials DME: submission H1 2021 (LMI070) Beovu® LXH254 BRAF/NRASm melanoma, RVO, diabetic retinopathy SMA mRAS/RAF NSCLC

ECF843 (Dry eye: Ph2 readout H2 2021), LNA043 (Osteoarthritis: Ph2b start H1 2021), ‘Wild Cards’ CSJ117 (Asthma), QBW251 (COPD), NIS793 (Solid tumors)

14 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Marie-France Tschudin President, Novartis Pharmaceuticals

15 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Pharmaceuticals portfolio continues to rejuvenate with 43% sales driven by recent launches and growth drivers

Pharmaceuticals net sales FY 2020: Net sales up +5% USD bn, growth in % cc . Growth drivers and launches growing +33%, despite pandemic conditions: Recent launches1 now represent 43% of the pharmaceutical sales Growth drivers2 Mature products3 Portfolio shift continues to lay foundation for future growth +5% . Cosentyx® and Entresto® contributed USD 6.5bn, growing +23% cc YoY 23.3 24.3 . Key approvals and launches in 2020 include: 0.7 1.9 - Kesimpta® in US 7.1 +33% 8.6 - Leqvio® in EU - Cosentyx® nr-axSpA in US and EU 15.5 13.8 -10% . Launched new products or new major indications in all 5 franchises

FY 2019 FY 2020

1. Zolgensma®, Xiidra®, Beovu® , Mayzent®, Aimovig®, Luxturna®, Kesimpta® , Enerzair® and Atectura®. 2. Cosentyx®, Entresto®, Xolair® , Ilaris® 3. All other brands.

16 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Cosentyx® Q4 sales up 13%, maintaining strong position in dermatology and outgrowing rheumatology market

Sales evolution Robust Q4 performance despite continued COVID-19 impact USD m, % cc . COVID-19 market impact: patient visits at 70%-80% vs. pre-COVID-191 Ex-US . Demand driven by clinical profile, strong access, execution excellence US 4.0bn (+13%) . Q4 YoY TRx grew faster than the market in US for PsO and SpA: 3.6bn - PsO: +10% vs. market +7%, maintaining strong NBRx share ~16%2 1,109 3 1,012 - SpA: +18% vs. market +9%, leading NBRx share ~30% 937 965 930 944 858 423 791 372 336 354 354 330 Catalysts for continued strong growth 324 317 . Increased biologics penetration in existing indications (all regions) . China NRDL listing for PsO and AS 601 611 614 640 686 474 534 576 . 300mg auto-injector & pre-filled syringe approved by EMA . Clinical data readout (ULTIMATE): significant reduction in synovitis Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 . Expansion to up to 10 indications/label expansions planned (e.g. HS, JIA)

JIA – Juvenile idiopathic arthritis HS – Hidradenitis suppurativa TRx – Total Prescriptions NBRx – New-to-Brand Prescriptions EMA – European Medicines Agency NRDL – National Reimbursement Drug List PsO – Psoriasis AS – ankylosing spondylitis SpA – spondyloarthritis TRx growth is calculated by comparing product volume across two time periods (YoY refers to Q4 2020 compared with Q4 2019). NBRx share calculated as product NBRx volume divided by market NBRx volume. 1. IQVIA Visits Data; 2. IQVIA National Prescription Audit for Dermatology through December 2020; PsO market includes Enbrel®, Humira®, Siliq®, Skyrizi™, Stelara®, Taltz®, Tremfya® 3. IQVIA National Prescription Audit for Rheumatology through December 2020; SpA market includes Cimzia®, Enbrel®, Humira®, Simponi®, Stelara®, Taltz®, Tremfya®

17 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Entresto® grows 44% in 2020 based on demand as an essential, first-choice treatment in heart failure

Sales evolution Strong momentum across geographies continues in Q4 USD m, % cc . US demand driven growth (+27% YoY) 1 Ex-US . China (>200% YoY) fueled ex-US growth US 2.5bn (+44%) . Europe delivered strong double-digit growth (+32% YoY) 1.7bn 716 632 Confidence in future growth 569 580 518 . Increasing penetration in HFrEF: only 25% currently treated2 421 430 354 357 272 318 233 276 . A direct-to-ARNI approach is now recommended in de novo patients by ACC 3 200 210 in the 2021 ECDP 158 362 285 293 308 314 199 221 220 LCM . Extended use in the treatment of HFpEF (US, Q1 2021) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 . PARADISE-MI trial on track for read-out in Q2 2021 2019 2020

ACC – American College of Cardiology HFrEF – Heart failure with reduced ejection fraction. HFpEF – Heart failure with preserved ejection fraction. CHF – Congestive Heart Failure. Post-AMI – post Acute Myocardial Infarction 1. US NBRx - IMS New to Brand Q4 vs Q3. Weekly NBRx averaged ~4,000 for the Q4 period up to 25 Dec 2020 2. Eligible patients defined as prevalent HFrEF patients within each market’s label. G7 = US, CA, JP, DE, FR, IT, UK 3. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway (ECDP) for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction (in publication). https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022

18 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Positive FDA AdComm supports extending the use of Entresto® to more HF patients, building on leading position in rEF

Unmet need and value of Entresto® confirmed Preparing for launch

. Recognition of highest effect in ejection fraction . Disease burden significant with frequent HF below normal1 hospitalizations, emergency rooms and urgent office visits . 12:1 vote in favor of extending use Depending on label, US addressable population . Understanding of HF is evolving putting . dichotomous classification in question2 could be 1.5m to 3m Strong experience and footprint in cardiology . Confirms strong unmet need . . Regulatory decision expected Q1 2021 . Expect to maintain leading access position . Uptake likely gradual due to lack of consensus guidelines

1. LVEF pooled analysis PARADIGM/PARAGON. Solomon S et al. 2020 Circulation. 2. Dichotomous classification of HFrEF and HFpEF is not adequately capturing treatment effect as discussed by FDA AdComm on Entresto (15 Dec 2020) and spironolactone (16 Dec 2020), incl. CHARM study (Lund et al. European Journal of Heart Failure (2018) 20, 1230–1239); TOPCAT study (Solomon et al. European Heart Journal (2016) 37, 455–462)

19 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Kesimpta® on track to become a 1st choice high efficacy DMT for patients, physicians and payers; preparing for RoW launches

Solid launch progress during pandemic 2021 priorities for acceleration

Broad payer >150m (~73%) US commercial lives Pull-through access, driving conversion coverage have unrestricted coverage or single step edit to paid product with sales ramp up in H2 coverage including big 3 plans1

Comprehensive 100% target prescribers reached2,3 Drive breadth, depth of HCP adoption, increase engagement F2F engagement with pandemic recovery

Broad adoption ~1000 patients treated in 1st 4 months Intensify patient activation through DTC and of launch4, 17% naive5 omni-channel engagement

Positive customer 80% of free Rx filled within 1 week average6 Maintain and build experience

Pandemic impact Restricted F2F interactions, patient visits down Impact expected to continue into H1 on MS Market 15-20%7, NBRx down 12%8

1. United Healthcare & OptumRx, CVS Caremark & Aetna, ESI Commercial, based on payer wins & associated lives covered 2. Internal target list having at least one contact through the hybrid F2F/ digital model 3. IQVIA BrandImpact. MS Promotional Activities Analysis. Neurology Panel. End Nov 2020. 4. IQVIA National Prescription Audit NBRx data through W/E 01/01 5. Based on start forms. 6. Novartis HUB and Direct to Specialty Pharmacy data 7. Symphony APLD Jan-Oct 2020 vs PY 8. Internal estimate; IQVIA Weekly NBRx w/e 20-Mar 2020 to 1-Jan 2021 vs PY

20 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Leqvio®: Expect gradual ramp in Europe, building foundation to be stronger out of the gate upon approval in US

Progressing approvals Preparing launches

First prescriptions expected February with EC approval December 2020 initial focus on population at high CV risk

On track for Q3 2021 launch in Completed 10 additional filings in RoW collaboration with NHS England

Advancing infrastructure building with CRL response plan submission Q2/Q3 2021 healthcare systems

21 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Focus in 2021 will be launches and preparing for next big bets, building on the strong foundation

Next wave of launches

Deliver on new launches Iptacopan: educate on complement- driven renal and hematologic diseases Maximize growth drivers Kesimpta®: enable broad HCP adoption, fast and simple access Iscalimab: create awareness on unmet Cosentyx®: deliver nr-axSpA launch, need LCM addressing 7m additional patients Leqvio®: establish broad and affordable access, addressing adherence, system Ligelizumab: leverage dermatology / ® Entresto : drive penetration in CN, barriers allergology footprint to expand use of launch in JP, expansion into pEF and biologics in CSU post-AMI Beovu®: restore evidence-based confidence to treat, expansion into Pelacarsen: drive Lp(a) awareness and DME/ RVO standard protocol testing Branaplam: drive biomarkers awareness and engage HD community on early treatment

Nr-axSpA – non-radiographic axial spondyloarthritis, pEF – preserved ejection fraction, post-AMI – post acute myocardial infarction, DME – diabetic macular edema, RVO – retinal vein occlusion, Lp(a) – lipoprotein (a)

22 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Susanne Schaffert President, Novartis Oncology

23 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Continued momentum on growth drivers and launches more than offset generic erosion in Q4 and FY 2020

Oncology net sales FY 2020: Net sales up +3% USD bn, % cc . Growth drivers and launches up +29%, despite pandemic conditions Recent launches1 . Embarked on virtual launches with Adakveo® and Tabrecta® Growth drivers2 Base business4 Gx3 Q4: Continued momentum of growth drivers and recent launches +3% . Promacta® / Revolade® (USD 471m, +23%) ® 14.4 14.7 . Jakavi (USD 376m, +24%) 1.3 0.2 2.1 . Tafinlar® + Mekinist® (USD 408m, +13%) 0.2 +29% . Kymriah® (USD 141m, +42%) 3.9 4.6 . Kisqali® (USD 184m, +18%) 3.7 0.9 3.6 -1% Q4: Offset Gx erosion, COVID-19 impact 5.5 4.4 -19% . Generic impact mainly from Afinitor®, Exjade® . Lutathera® (USD 109m, +1% cc) continued impact from COVID-19 FY 2019 FY 2020

All growth rates in cc. 1. Recent launches include Kisqali®, Lutathera®,Kymriah®, Piqray®, Adakveo® , Tabrecta® 2.Growth drivers include Promacta®/Revolade®, Tafinlar®+ Mekinist®, Jakavi® (marketed by Novartis ex-US) 3. Gx include Afinitor®, Exjade®, Glivec® and Sandostatin® 4. Base business – other brands

24 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Kisqali®: Strong growth as the only CDK4/6i proven to extend lives in two Ph3 trials

Sales evolution . Delivered strong growth (+45% cc) and market share gains (+4.8%1) in 2020, USD m, % cc driven by unprecedented overall survival (OS) benefit from 2 pivotal Ph3 trials

Ex-US . CDK4/6i market still depressed due to COVID-19 (NBRx down -15% vs. PY) US . Longest median OS among all Ph3 trials in aBC: nearly 5 years in pre- +45% menopausal patients

687 . Pooled data from MONALEESA studies presented at SABCS confirmed efficacy across luminal and ET resistant HER2-E patient subtypes 480 369 . Ability to selectively and preferentially inhibit CDK4 may restore endocrine sensitivity in these more aggressive tumors 230 . NATALEE adjuvant study in intermediate and high risk populations (70% of adjuvant patients) final readout expected 2022 250 318

FY 2019 FY 2020

1. Patient share, October YTD vs PY

25 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Kymriah®: Double-digit growth in all regions despite pandemic

Sales evolution . Sales grew +68% cc in 2020, despite COVID-19 impact on healthcare systems USD m, % cc . Continued to expand our global footprint: Ex-US − 27 countries covering at least 1 indication US +68% − 290+ qualified treatment centers − FBRI approved for commercial supply (previous approvals: Stein, Les Ulis) 474 . Increased manufacturing capacity ~70% vs. PY, improved process robustness

. New data at ASH: 269 278 − ELARA interim analysis showed Kymriah® is effective in extensively pre-treated patients with r/r FL: CR 65%, ORR 83%; submission expected 2021 119 − JULIET updated efficacy results showed continued durable responses for patients with r/r DLBCL: 2-year progression-free survival rate 33% 159 205 . Advanced our CAR-T pipeline (new indications) and CAR-T manufacturing platform

FY 2019 FY 2020

FBRI – Foundation for Biomedical Research and Innovation

26 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Asciminib: Superior efficacy and safety profile confirms potential to transform standard of care in CML

ASCEMBL is the 1st head-to-head pivotal trial vs. a 2nd generation TKI

Major Molecular Response rate at 24 weeks 25.5% . Ph3 ASCEMBL study in 3L+ CML-CP: demonstrated statistically 1.9x1 significant superiority in efficacy vs. bosutinib and a favorable 13.2% safety profile n=1 n=7 57 6 . MMR rate at 24 weeks: 25.5% vs. 13.2% with bosutinib, meeting

% of patients of % primary endpoint; consistent across most major demographic and Asciminib Bosutinib prognostic subgroups

Complete Cytogenetic response at 24 weeks . AEs leading to dose adjustment or interruption with asciminib vs. 40.8% bosutinib were 37.8% (n=156) and 60.5% (n=76), respectively; AEs leading to discontinuation were 5.8% and 21.1%, respectively 1.7x 24.2% . Global regulatory submissions planned in H1 2021; further

plans to expand into earlier lines underway % of patients of % Asciminib Bosutinib

1. After adjusting for major cytogenetic response (MCyR) status at baseline. CML-CP, chronic myeloid leukemia-chronic phase; MMR, major molecular response; AE, adverse event;

27 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation 2021: Maximize momentum for our growth drivers and new launches, while preparing for next big bets

Next wave of launches

177Lu-PSMA: Further evolve commercial Deliver on new launches infrastructure for best-in-class launch Canakinumab: Focus on medical education on Maximize growth drivers Piqray®: Maximize US launch momentum and pro-tumor inflammation expand further to EU markets Sabatolimab: Build awareness of the dual Kisqali®: Continue strong growth driven by M3 Adakveo®: Enable access in larger US mechanism of action of TIM-3 and its potential and M7 OS data accounts and continue global expansion in MDS/AML Kymriah®: Drive growth in pALL and DLBCL, Tabrecta®: Maximize the first mover advantage TNO155: Advance a first-in-class inhibitor of leveraging a differentiated profile and increased as the first and only MET inhibitor available for SHP2 across 5 combination trials in NSCLC and manufacturing capacity and reliability patients in the US CRC Lutathera®: Unlock potential in community Asciminib: Drive awareness of CML unmet LXH254: Advance potentially best-in-class B/C- setting and grow use in earlier lines of treatment need and the importance of STAMP and launch RAF inhibitor in RAS/RAF mutant melanomas Promacta®/Revolade®: Growth in ITP and successfully in US and lung cancers uptake in 1L SAA in the US and Japan Jakavi®: Continue strong growth in PV and MF, while launching GVHD Tafinlar® + Mekinist®: leverage potential in adjuvant melanoma and NSCLC

28 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Expanding our pipeline with in-licensing of tislelizumab, a late-stage PD-1 inhibitor, from BeiGene1

Tislelizumab Strategic rationale

Accelerate IO market entry with backbone PD-1 . PD-1 market expected to reach USD 63bn by 2026 . Tislelizumab already approved in China; 15 potentially registration-enabling clinical trials currently ongoing, with first ex-China filing expected in 2021 . Key indications include NSCLC, HCC, esophageal and gastric cancer

Unlock combination potential with Novartis assets . Multiple combination opportunities identified with Novartis portfolio, across all 4 therapeutic platforms . Open the door to potential broader strategic collaboration with BeiGene Deal terms Anti-PD-1 monoclonal antibody . Upfront payment of USD 650m plus royalties and milestone payments specifically designed to minimize . Novartis obtains development and commercialization rights in ex-China regions2 binding to FcγR on macrophages . Closing expected H1 2021, deal subject to normal closing conditions1

1. Novartis signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China on January 11, 2021. Closing of the transaction is subject to receiving antitrust clearance. Until closing, BeiGene will continue to have control of tislelizumab 2. Ex-China regions include the US, Canada, Mexico, the EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan; BeiGene retains the rights to tislelizumab in China and other countries

29 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Harry Kirsch Chief Financial Officer

Financial review and 2020 guidance

30 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation 2020 financial results in line with guidance As revised in Q3 investor call

Group full year guidance FY 2020 vs. PY In cc in cc

“Sales expected to grow mid single digit assuming return to normal prescription dynamics. 3%  3 to 4% range in case of resurgence of COVID-19” “Core operating income to grow low double digit to mid teens” 13% 

31 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Solid FY performance on top and bottom line

Continuing operations 1 Q4 Change vs. PY FY Change vs. PY USD million 2020 % USD % cc 2 2020 % USD % cc 2

Net Sales 12,770 3 1 48,659 3 3

Core Operating income 2 3,501 1 2 15,416 9 13

Operating income 2,644 45 51 10,152 12 19

Net Income 2,099 86 93 8,071 13 20

Core EPS (USD) 2 1.34 2 3 5.78 9 13

EPS (USD) 0.92 84 93 3.55 14 21

Free Cash Flow 2 3,342 -4 11,691 -10

1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions 2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report

32 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Core margin expansion of +2.8% points FY Innovative Medicines core margin at 35.0%

Continuing operations1,2

Q4 2020 FY 2020

Core operating Core operating Net sales income Core margin Net sales income Core margin change vs. PY change vs. PY Core margin change vs. PY change vs. PY change vs. PY Core margin change vs. PY (in % cc) (in % cc) (%) (%pts cc) (in % cc) (in % cc) (%) (%pts cc)

Innovative Medicines 1 3 31.4 0.7 4 11 35.0 2.2

Sandoz 0 3 20.8 0.8 0 15 24.2 3.3

Continuing Operations 1 2 27.4 0.4 3 13 31.7 2.8

1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions 2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report

33 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation FY 2020 free cash flow decreased to USD 11.7bn

Continuing operations1 free cash flow2 USD billion

Key drivers vs. PY: -10% 12.9 + Higher operating income 11.7 (adjusted for non-cash items)

− Payments for legal matters

− Lower divestment proceeds

FY 2019 FY 2020

1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions 2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report

34 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation 2021 Novartis full year guidance Barring unforeseen events; growth vs. PY in cc

Continuing operations | full year guidance1 vs. PY (cc)

Sales expected to grow low to mid single digit . IM Division expected to grow mid single digit . Sandoz expected to be broadly in line with prior year

Core operating income expected to grow mid single digit, ahead of sales

1. Key assumptions: . Our guidance assumes that we see a return to normal global healthcare systems including prescription dynamics by mid 2021 . In addition, we assume that no Gilenya and no Sandostatin LAR generics enter in 2021 in the US

35 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Q1 2021 Sales expected to decline due to PY COVID-19 forward purchasing of approximately +0.4bn

Sales growth vs. PY %pts, cc 13 Q1 2020 3 0.4bn Forward purchasing (approximately 3%pts of Q1 growth) 2020 Actuals

Q1 FY Q1 2021 Low to mid Broadly in line vs. PY excluding PY single digit forward purchasing impact 2021 Key assumption: Illustrative Return to normal prescription dynamics of healthcare systems by mid 2021

Low to mid single digit

36 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Expecting margin expansion with Core OpInc growth magnitude lower in 2021 driven by increased launch investments

2021 pushes and pulls + - Growth drivers and Kesimpta® launch Increased investments uptake benefiting from return to normal in launches and pre-launches, including global healthcare systems by early H2 Kesimpta® and Leqvio®

Productivity programs Increased development costs tislelizumab1 Continue new ways of working Increased investments into growth drivers assuming physician access normalizes as of mid year

1. Novartis signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China on January 11, 2021. Closing of the transaction is subject to receiving antitrust clearance. Until closing, BeiGene will continue to have control of tislelizumab

37 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation FY 2021 Guidance on other financial KPIs Barring unforeseen events; growth vs. PY in cc

Continuing operations1 | full year guidance vs. PY (cc)

Core Net Expenses expected to be broadly in line vs. 2020 Financial Result

Core Tax Rate 2021 Core tax rate expected to be around 16%

1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions

38 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Novartis proposes 24th consecutive dividend increase to the AGM: 3.00 CHF / share1

2020 dividend yield 3.6%2 2020 dividend growth 1.7%3

3.5 4

3.0 CHF dividend USD dividend

2.5 3.40 USD

USD 3.12 USD

CHF 3.00 CHF CHF 2.95 CHF 2.0

1.5

1.0

0.5

0.0 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

1. Proposal to shareholders at the 2021 Annual General Meeting, taking place on March 2, 2021 2. Based on closing share p rice of CHF 83.65 at end of business year 2020 (December 30, 2020) 3. In CHF 4. Converted at historic exchange rates at the dividend payment dates as per Bloomberg for 2020, assumes an exchange rate of USD/CHF of 0.88106 as of December 31, 2020

39 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Expected currency impact for full year 2021

Currency impact vs. PY %pts, assuming late-January exchange rates prevail in 2021

FX impact on Net sales FX impact on Core operating income

4 3 to 4 3 2 2 0 -1 -4 Q4 FY Q1 FY Q4 FY Q1 FY

2020 2021 2020 2021

Actual Simulation

40 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Vas Narasimhan Chief Executive Officer

41 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Made significant strides in building trust with society and in integrating ESG across every aspect of our company

Key ESG developments over the past 12 months and selected aspirations

Ethical Pricing Global Health Corporate Governance & Standards & Access Challenges Citizenship Transparency

Resolved material legacy Introduced 100+ Expanded our Africa sickle Strong COVID-19 response ESG index launched compliance issues Emerging Market Brands cell disease program Integrating D&I efforts Reporting in line with TCFD Launched Code of Ethics Issued sustainability- Advancing pipeline of across our operations Working towards integrated linked bond novel malaria treatments reporting

Select 200% increase in SITs 50% increase in our Full carbon, plastic and ESG targets embedded into commitments patient reach by 20251 Flagship Programs’ reach water neutrality by 2030 executive remuneration by 20251

Significant improvements recognized by third party ESG rating agencies. Ranked no.2 in 2021 Access to Medicines Index just announced

SIT – Strategic innovative therapies 1. As defined in ESG bond prospectus More details in Novartis in Society Report: www.novartis.com/nisreport2020

42 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Confident that we will grow top and bottom line every year to 2025 and meet external expectations

Analyst consensus sales USD billion +4% CAGR

60

49

2020 Growth Drivers1 Launches2 Other/Pipeline Sandoz Gx Brands3 2025 Actual Consensus IM margin IM margin External expectations based 35.0% on analyst consensus 37.6%

1. Cosentyx®, Entresto®, Zolgensma®, Kisqali®, Mayzent®, Tafinlar+Mekinist®, Jakavi®, Beovu®, Xiidra®, Aimovig®, Xolair®. 2. Lutathera®, Kymriah®, Piqray®, Adakveo®, Kesimpta®, Leqvio®, Tabrecta®, Asciminib. 3. Brands with 2024 consensus sales lower than 2019 actual sales (Glivec®, Tasigna®, Afinitor®, Votrient®, Promacta®, Exjade®, Sandostatin®, Galvus®, Gilenya®, Lucentis®). Source: Novartis Investor Relations in-house consensus as of November 12, 2020.

43 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Conclusion

Delivered on our strategic and operational commitment in 2020

Third successive year of increases in sales, core operating income and margin

Progressing the pipeline and key approvals in 2020: Kesimpta® in US, Leqvio®, Zolgensma® in EU, Tabrecta® in US, new indications for Cosentyx®

Expecting top and bottom line growth every year through 2025

44 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Appendix Strong FY operational performance from growth drivers

Key growth driver sales FY 2020 Key growth drivers and launches, as % of Innovative Medicines sales Sales Growth vs. PY Growth vs. PY USD Million USD Million cc 49% Adakveo® 771 2,497 44% Mayzent® 920 559 151% 40% Beovu® Piqray® 3,995 444 13% Xiidra® 1,738 322 23% 32% Lutathera® ® 1,339 225 20% Kymriah 26% Kisqali® 687 207 45% Ilaris® 1,542 204 16% Zolgensma® Jakavi® 320 204 176% Tafinlar+Mekinist® 873 202 31% Promacta®

® 474 196 68% Entresto Cosentyx® 376 184 95% FY 2017 FY 2018 FY 2019 FY 2020 Other1 190 155 nm 1. Includes Tasigna®, Xolair®, Aimovig®, Tabrecta®, Luxturna® , Kesimpta®, Enerzair ® and Atectura® nm – not meaningful

46 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Net debt increased by USD 8.6bn mainly due to The Medicines Company acquisition

-8.6

-15.9

-7.0 -2.1 -1.2 -24.5

-10.0 11.7 Dec. 31, 2019 Dividends M&A Free Cash Flow2 Treasury share Others Dec. 31, 2020 transactions1 transactions, net

1. Mainly the acquisition of The Medicines Company for USD 9.6bn. 2. Free cash flow is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report.

47 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Advancing our innovation agenda over the last 3 years

2018 2019 2020

Major DLBCL Migraine SPMS HR+ BC Sickle cell Relapsing MS NSCLC Hyperlipidemia approvals1 Lutathera® Adj Melanoma NET SMA nAMD Asthma Nr-axSpA CRSwNP

1st line SAA Major submissions2 SPMS HR+ BC nAMD NSCLC asthma HFpEF Hyperlipidemia

SMA 1st line SAA Sickle cell Relapsng MS Nr-axSpa

Major Asciminib readouts Advanced BC HR+ BC nr-axSpA Relapsing MS HFpEF Chronic GvHD CML 3L DME (pivotal) Fevipiprant NSCLC SMA presymptomatic Asthma Follicular lymphoma

1. First approval in any market. 2. First submission in any market.

48 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation 2020 pipeline milestones ✓ Achieved H1 2020 H2 2020 ✕ Missed Regulatory Beovu® nAMD (EU/JP) ✓ Adakveo® Sickle cell disease (EU) ✓ ® ® decisions and Cosentyx nr-axSpA (EU/US) ✓ Tabrecta (capmatinib) NSCLC (US/JP) ✓ Cosentyx® AS (CN) ✓ Cosentyx® Pediatric psoriasis (EU) ✓ opinions ✓ Kesimpta® Relapsing MS (US) Cosentyx® nr-axSpA (JP) ✓ (H2 2020) HR+/HER2- aBC with PIK3CA Piqray® Entresto® HFpEF (US) Q1 20212 mutation (EU) ✓ Enerzair® Asthma (EU/JP) ✓ Leqvio (inclisiran) Hyperlipidemia (US) ✕4 Tafinlar® & Mekinist® Adjuvant melanoma (CN) ✓ Hyperlipidemia (EU) ✓ Xiidra® DED (EU) ✕ Xolair® Nasal Polyposis (US/EU) ✓ Zolgensma® IV SMA (EU/JP) ✓ Major Entresto® HFpEF (US) ✓ Alpelisib (BYL719) PROS (US) H2 2021 3 expected Inclisiran (KJX839) Hyperlipidemia (EU) ✓ AVXS-101 IT SMA (US) ✕ Juvenile PsA / enthesitis-related Cosentyx® Q2 2021 submissions arthritis (US/EU) Spartalizumab (PDR001) Negative Metastatic melanoma (US/EU) and Tafinlar® & Mekinist® read-out 177Lu-PSMA-617 mCRPC (US) Q4 2021 Entresto® Post-acute MI1 ✓ Asciminib (ABL001) CML 3L ✓ Major ® expected trial Tropifexor (LJN452) NASH ✓ Beovu DME ✓ UNR844 Presbyopia ✓ Jakavi® chronic GVHD ✓ readouts* Kisqali® aBC (MONALEESA-2 OS) Q4 2021 177Lu-PSMA-617 mCRPC H1 2021

*Achieved = on-time readout of data, irrespective of trial outcome 1. Planned study readout 2021; preplanned DMC interim analysis readout completed in March 2.Received positive FDA Advisory Committee recommendation for use in patients with HFpEF Dec 2020 3. FDA recommended pivotal confirmatory study to supplement existing STRONG data 4. Novartis received a CRL from the FDA due to unresolved facility inspection-related conditions at a third-party manufacturing facility in Europe. FDA has not raised any concerns related to the efficacy or safety of inclisiran. Response to CRL planned to be submitted Q2 - Q3 2021

49 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation 2021 key pipeline milestones1

H1 2021 H2 2021 ✓ Achieved ✕ Missed

Regulatory Entresto® HFpEF (US) Cosentyx® Pediatric psoriasis (US / CN / JP) decisions and opinions Kesimpta® Relapsing MS (EU / JP)

Major Leqvio® Hyperlipidemia (US)2 Asciminib (ABL001) CML 3L (JP) expected Jakavi® Acute and chronic GvHD (EU, JP) Beovu® DME (JP) submissions Tabrecta® NSCLC (EU) Alpelisib (BYL719) PROS (US) Beovu® DME (US / EU) Kymriah® r/r Follicular lymphoma (US / EU / JP) Asciminib (ABL001) CML 3L (US /EU) Major Iptacopan (LNP023) Ph2 - IgAN Canakinumab (ACZ885) Ph3 - NSCLC 1L expected trial Iptacopan (LNP023) Ph2 - C3G ECF843 Ph2 - Dry eye * readouts Entresto® Ph3 - Post-AMI Ligelizumab (QGE031) Ph3 - CSU3 Canakinumab (ACZ885) Ph3 - NSCLC 2L Kisqali® aBC (MONALEESA-2 OS) 177Lu-PSMA-617 Ph3 - mCRPC Remibrutinib (LOU064) Ph2 - CSU Cosentyx® Ph3 - Juvenile PsA Cosentyx® Ph3 - HS Sabatolimab (MBG453) Ph2, MDS Kymriah® Ph3, r/r DLBCL 1st relapse

*Achieved = on-time readout of data, irrespective of trial outcome 1. 2021 Key milestone table may evolve based on read-out outcomes as well as BD&L activities 2. Novartis received a CRL from the FDA due to unresolved facility inspection-related conditions at a third-party manufacturing facility in Europe. FDA has not raised any concerns related to the efficacy or safety of inclisiran. Response to CRL planned to be submitted Q2 - Q3 2021 3. Q4/2021-Q1/2022 potential COVID impact

50 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation COVID-19 outlook for 2021

Therapeutic areas with highest potential for To date, minimal impact (< 3 months) expected for ongoing COVID-19 impact in 2021 majority of regulatory submissions through 20251

Uncertainty remains about FDA’s ability to conduct foreign manufacturing inspections

Robust mitigations in place for clinical trial execution: Ophthamology Respiratory Diseases . COSSET (COVID-19 Site Surveillance Tool): predictive tool for proactively adapting to dynamic COVID-19 impacts at site level . > 35k remote monitoring visits since March . > 2k direct-to-patient medical delivery shipments . < 24 hours to detect / respond to site level actions Kidney Disease / . Active home nursing and virtual safety assessments Transplant Dermatology . Novartis Digital Recruitment (NDR) implemented for new trial starts

1. As of end of December 2020

51 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Our pipeline projects at a glance

Phase 1/2 Phase 3 Registration Total ONCOLOGY 51 22 0 73

PHARMACEUTICALS 67 21 5 93 Cardiovascular, Renal, Metabolism 12 4 2 18 Immunology, Hepatology, Dermatology 27 9 1 37 Neuroscience 7 2 1 10 Ophthalmology 6 3 0 9 Respiratory 9 2 0 11 Global Health 6 1 1 8 BIOSIMILARS 0 1 0 1 Total 118 44 5 167

52 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Novartis submission schedule New Medical Entities: Lead and supplementary indications

2021 2022 2023 2024 ≥2025

177Lu-PSMA-617 Lead ligelizumab Lead ECF843 Lead Icenticaftor Lead 177Lu-NeoB Lead iscalimab Lead NIS793 Lead AAA617 QGE031 Dry eye QBW251 AAA603 CFZ533 Solid tumors mCRPC 3L CSU COPD Multiple Solid Tumors Renal Tx

asciminib Lead iptacopan Lead SAF312 Lead 177Lu-PSMA-R2 Lead ianalumab Lead OAV201 Lead ABL001 LNP023 COSP AAA602 VAY736 AVXS-201 CML 3L PNH Prostate cancer Sjögren’s syndrome Rett syndrome

sabatolimab Lead UNR844 Lead CEE321 Lead LMI070 Lead pelacarsen Lead MBG453 Presbyopia Atopic Dermatitis Huntington’s disease TQJ230 HR-MDS CVRR-Lp(a)

cipargamin Lead LNA043 Lead remibrutinib KAE609 Osteoarthritis LOU064 Malaria severe CSU

CPK850 Lead LXE408 Lead spartalizumab Lead RP Visceral leishmaniasis PDR001

Malignant melanoma (combo) LEAD INDICATIONS CSJ117 Lead LXH254 Lead TNO155 Lead Asthma Solid tumors Solid tumors

ganaplacide Lead mavoglurant Lead tropifexor&cenicriviroc Lead LJC242 KAF156 AFQ056 NASH Malaria uncomplicated Cocaine use disorder

gevokizumab Lead MIJ821 Lead VPM087 Depression 1st line CRC / 1st line RCC

canakinumab LCM 177Lu-PSMA-617 LCM crizanlizumab LCM cipargamin LCM iptacopan LCM LMI070 LCM ACZ885 AAA617 SEG101 KAE609 LNP023 SMA NSCLC 2L Pre-taxane Sickle cell anaemia with crisis ped Malaria uncomplicated aHUS

canakinumab1) LCM canakinumab LCM ligelizumab LCM iscalimab LCM ianalumab LCM remibrutinib LCM ACZ885 ACZ885 QGE031 CFZ533 VAY736 LOU064 NSCLC 1L Adjuvant NSCLC CINDU Liver Tx AIH Sjögren’s syndrome

iptacopan LCM sabatolimab LCM iscalimab LCM ligelizumab LCM tropifexor&licogliflozin LCM LNP023 MBG453 CFZ533 QGE031 LJN452 C3G Unfit AML Sjögren’s syndrome Food allergy NASH (combos) iptacopan LCM iptacopan LCM LNP023 LNP023

IgAN iMN NEW INDICATIONS

1. Depending on timing of final read-out submission may move to early 2022.

53 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Novartis submission schedule Supplementary indications for existing brands

20211) 2022 2023 2024 ≥2025

alpelisib, BYL719 LCM Cosentyx LCM Cosentyx LCM Coartem LCM Aimovig LCM Jakavi LCM Mayzent LCM PROS secukinumab, AIN457 secukinumab, AIN457 artemether + lumefantrine, CCA566 erenumab, AMG334 ruxolitinib, INC424 siponimod, BAF312 PsA IVIV AS IVIV Malaria uncompl., formula for <5kg Pediatric Migraine Myelofibrosis (combination) Pediatric MS

Beovu LCM Cosentyx LCM Beovu LCM Cosentyx LCM Cosentyx LCM Jakavi LCM Piqray LCM brolucizumab, RTH258 secukinumab, AIN457 brolucizumab, RTH258 secukinumab, AIN457 secukinumab, AIN457 ruxolitinib, INC424 alpelisib, BYL719 DME AS H2H Diabetic retinopathy GCA Lichen Planus Pediatrics Chronic GVHD HNSCC 2/3L

Cosentyx LCM Cosentyx LCM Beovu LCM Jakavi LCM Cosentyx LCM Kymriah LCM Piqray LCM secukinumab, AIN457 secukinumab, AIN457 brolucizumab, RTH258 ruxolitinib, INC424 secukinumab, AIN457 tisagenlecleucel, CTL019 alpelisib, BYL719 Juvenile idiopathic arthritis Hidradenitis suppurativa RVO Pediatrics Acute GVHD Lupus Nephritis 1L high risk ALL, pediatrics & young adults HER2+ adv BC

Entresto LCM Entresto EU3) LCM denosumab BioS Tafinlar + Mekinist LCM leqvio LCM sacubitril/valsartan, LCZ696 sacubitril/valsartan, LCZ696 GP2411 dabrafenib + trametinib, DRB436 KJX839 Post-AMI Pediatric HF anti RANKL mAb Thyroid cancer CVRR-LDLC

Jakavi LCM Promacta LCM Kisqali LCM Tabrecta LCM ruxolitinib, INC424 eltrombopag, ETB115 ribociclib, LEE011 capmatinib, INC280 Chronic GVHD Radiation sickness syndrome HR+/HER2- BC (adj) Solid tumors

Jakavi LCM Promacta LCM Lutathera LCM ruxolitinib, INC424 eltrombopag, ETB115 177Lu-oxodotreotide2) Acute GVHD Food effect free formulation GEP-NET 1L G3

Kymriah LCM Tafinlar + Mekinist LCM Piqray LCM tisagenlecleucel, CTL019 dabrafenib + trametinib, DRB436 alpelisib, BYL719 r/r DLBCL 1st relapse HGG/LGG - Pediatrics TNBC

Kymriah LCM Xolair LCM Piqray LCM tisagenlecleucel, CTL019 omalizumab, IGE025 alpelisib, BYL719 r/r Follicular lymphoma Food allergy Ovarian cancer

Xolair LCM omalizumab, IGE025 Auto-injector

1. OAV101 (AVXS-101) IT filing timelines TBC based on HA feedback, preclinical studies to address partial clinical hold are on track 2. 177Lu-dotatate in US 3. Approved in US

54 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Novartis pipeline in registration 1 lead indications Lead indication

Immunology, Hepatology, Dermatology Cardiovascular, Renal, Metabolism Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) AIN457 Cosentyx® IL17A inhibitor 300 mg AI KJX839 Leqvio® siRNA (regulation of LDL-C) Hyperlipidemia2) LCZ696 Entresto® Angiotensin receptor/neprilysin HFpEF inhibitor

Neuroscience Global Health Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) OMB157 ofatumumab CD20 antagonist r MS1) LAM320 Lamprene® SMPD1 inhibitor Tuberculosis3)

1. Approved in US as Kesimpta® 2. Novartis received a CRL from the FDA due to unresolved facility inspection-related conditions at a third-party manufacturing facility in Europe, FDA has not raised any concerns related to the efficacy or safety of inclisiran. Response to CRL planned to be submitted Q2 - Q3 2021. 3. WHO Pre-Qualification

55 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Novartis pipeline in Phase 3 6 lead indications Lead indication

Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) AAA617 177Lu-PSMA-617 Targeted radioligand therapy mCRPC mCRPC pre-taxane AMG334 Aimovig® CGRPR antagonist Ped Migraine AAA6011) Lutathera® Targeted radioligand therapy GEP-NET 1L G3 BAF312 Mayzent® S1P1,5 receptor modulator Ped MS ABL001 asciminib BCR-ABL inhibitor CML 3L Adjuvant ACZ885 canakinumab IL-1b inhibitor NSCLC 1L NSCLC 2L NSCLC BYL719 Piqray® PI3Kα inhibitor HER2+ adv BC TNBC HNSCC 2/3L Ovarian cancer CTL019 Kymriah® CD19 CART r/r Follicular 1L high risk r/r DLBCL 1st Respiratory Disease lymphoma ALL, pediatrics relapse and young Code Name Mechanism Indication(s) adults IGE025 Xolair® IgE inhibitor Food allergy Auto-injector Tafinlar® + BRAF inhibitor + MEK inhibitor Thyroid cancer DRB436 Mekinist® ETB115 Promacta® Thrombopoietin receptor (TPO-R) Radiation sickness syndrome Food effect free formulation agonist Cardiovascular, Renal, Metabolism INC280 capmatinib Met inhibitor NSCLC EU2) Code Name Mechanism Indication(s) INC424 Jakavi® JAK1/2 inhibitor Acute GVHD Chronic GVHD KJX839 Leqvio® siRNA (regulation of LDL-C) CVRR-LDLC LEE011 Kisqali® CDK4 Inhibitor HR+/HER2- BC (adj) LCZ696 Entresto® Angiotensin receptor/neprilysin Post-AMI Pediatric HF3) MBG453 sabatolimab TIM3 antagonist HR-MDS inhibitor TQJ230 pelarcasen ASO targeting Lp(a) CVRR-Lp(a) Immunology, Hepatology, Dermatology Code Name Mechanism Indication(s) Global Health AIN457 Cosentyx® IL17A Inhibitor Lupus Nephritis Juvenile idiopathic arthritis AS H2H Code Name Mechanism Indication(s) IV regimen in PsA IV regimen in AS HS COA566 Coartem® - Malaria uncomplicated, new formulation <5kg patients QGE031 ligelizumab IgE Inhibitor CSU CINDU Food allergy

Ophthalmology Biosimilars Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) RTH258 Beovu® VEGF Inhibitor Diabetic retinopathy RVO DME GP2411 denosumab anti RANKL mAb Denosumab BioS

1. 177Lu-dotatate in US 2. Approved in US & JP 3. Approved in US

56 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Novartis pipeline in Phase 2 31 lead indications Lead indication

Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) BYL719 alpelisib PI3Kα inhibitor PROS BAF312 Mayzent® S1P1,5 receptor modulator Stroke BLZ945 BLZ945 CSF-1 Inhibitor Solid tumors BLZ945 BLZ945 CSF-1 Inhibitor ALS DRB436 Tafinlar® + Mekinist® BRAF inhibitor + MEK inhibitor HGG/LGG - Pediatrics LMI070 branaplam mRNA splicing modulator SMA INC280 capmatinib Met inhibitor Solid tumors NSCLC NSCLC MIJ821 MIJ821 NR2B Inhibitor Depression (Combo) (Combo) OAV101 AVXS-101 Survival motor neuron (SMN) SMA IT1) INC424 Jakavi® JAK1/2 inhibitor Myelofibrosis (combination) Pediatrics acute Pediatrics gene therapy GVHD chronic GVHD LXH254 LXH254 cRAF inhibitor Melanoma (combo) MBG453 sabatolimab TIM3 antagonist Unfit AML Respiratory Disease NIR178 NIR178, spartalizumab Ad2AR inhibitor, PD1 inhibitor Cancers Code Name Mechanism Indication(s) NIS793 NIS793 TGFB1 inhibitor Pancreatic cancer CMK389 CMK389 IL-18 inhibitor Pulmonary sarcoidosis PDR001 spartalizumab PD1 inhibitor Metastatic melanoma (combo) CSJ117 CSJ117 TSLP inhibitor Asthma SEG101 crizanlizumab P-selectin Inhibitor Ped sickle cell anaemia with crisis DFV890 DFV890 - COVID-19 related pneumonia LOU064 remibrutinib BTK inhibitor Asthma Immunology, Hepatology, Dermatology MAS825 MAS825 - COVID-19 related pneumonia QBW251 icenticaftor CFTR potentiator COPD Code Name Mechanism Indication(s) VAY736 ianalumab BAFF-R inhibitor IPF ADPT02 ADPT02 - NASH (Combos) AIN457 Cosentyx® IL17A inhibitor GCA Lichen planus CFZ533 iscalimab CD40 inhibitor Renal Tx Sjögren’s HS Liver Tx Cardiovascular, Renal, Metabolism LJC242 tropifexor & cenicriviroc FXR agonist, CCR2 inhibitor NASH (combos) Code Name Mechanism Indication(s) LJN452 tropifexor & licogliflozin FXR agonist NASH (combos) CFZ533 iscalimab CD40 inhibitor Lupus nephritis T1DM LNA043 LNA043 ANGPTL3 agonist Osteoarthritis HSY244 HSY244 - Atrial fibrillation LOU064 remibrutinib BTK inhibitor CSU Sjögren’s ® LRX712 LRX712 - Osteoarthritis LCZ696 Entresto Angiotensin receptor/neprilysin nHCM inhibitor LYS006 LYS006 Anti-inflammatory Acne Colitis ulcerative HS LMB763 nidufexor FXR agonist Diabetic nephropathy MAS825 MAS825 - NLRC4-GOF indications LNP023 iptacopan CFB inhibitor PNH IgAN C3G iMN aHUS VAY736 ianalumab BAFF-R inhibitor Sjögrens AIH SLE LTW980 LTW980 - Hypertriglyceridemia Ophthalmology Global Health Code Name Mechanism Indication(s) CPK850 CPK850 RLBP1 AAV RP Code Name Mechanism Indication(s) ECF843 ECF843 rh-Lubricin Dry eye AFQ056 AFQ056 mGluR5 Antagonist Cocaine use disorder LKA651 LKA651 EPO inhibitor DME KAE609 cipargamin PfATP4 inhibitor Malaria severe Malaria uncomplicated SAF312 SAF312 TRPV1 antagonist COSP KAF156 ganaplacide - Malaria uncomplicated UNR844 UNR844 Disulfide bonds modulator Presbyopia LXE408 LXE408 Protozoan inhibitor Visceral leishmaniasis 1. Preclinical studies to address partial clinical hold are on track

57 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Novartis pipeline in Phase 1 (1 of 2) 36 lead indications Lead indication

Oncology Code Name Mechanism Indication(s) AAA603 177Lu-NeoB Radioligand therapy target GRPR Multiple solid tumors AAA602 177Lu-PSMA-R2 Radioligand therapy target PSMA Prostate cancer ADPT01 ADPT01 - TNBC (combos) Colorectal cancer (combos) ADPT03 ADPT03 BCL11A Sickle cell anemia CSJ137 CSJ137 Growth factor inhibitor Anaemia CTL019 Kymriah® CD19 CART Lymphoma DKY709 DKY709 + spartalizumab Novel immunomodulatory agent Cancers EGF816 nazartinib + LXH254, ribociclib, capmatinib, opdivo, mekinist EGFR inhibitor NSCLC (combo) HDM201 HDM201 + MBG453, venetoclax MDM2 inhibitor Haematological malignancy JBH492 JBH492 - Haematological malignancy JEZ567 JEZ567 CD123 CART AML KAZ954 KAZ954 - Solid tumors LHC165 LHC165 + spartalizumab TLR7 agonist Solid tumors LXF821 LXF821 EGFR CART Glioblastoma multiforme LXH254 LXH254 (combos) cRAF inhibitor Solid tumors Solid tumors MAK683 MAK683 EED inhibitor Cancers MCM998 MCM998, LXG250 BCMA CART, CD19 CART Multiple myeloma MIK665 MIK665 MCL1 inhibitor AML (combo) NIS793 NIS793, spartalizumab TGFB1 inhibitor Solid tumors NIZ985 NIZ985, spartalizumab IL-15 agonist Solid tumors NZV930 NZV930, spartalizumab, NIR178 CD73 antagonist Solid tumors PDR001 spartalizumab (combos) PD1 inhibitor AML Solid tumors (combo) PHE885 PHE885 BCMA cell therapy Multiple myeloma SQZ622 SQZ622 CD123xCD3 modulator AML TNO155 TNO155 SHP2 inhibitor Solid tumors (single agent) Solid tumors (combo) Solid tumors (combo) VAY736 ianalumab + ibrutinib BAFF-R inhibitor Haematological malignancy VOB560 VOB560 - Cancers VPM087 gevokizumab IL1B Antagonist CRC 1st line WNT974 WNT974 + spartalizumab Porcupine Inhibitor Solid tumors WVT078 WVT078 - Multiple myeloma YTB323 YTB323  ibrutinib CD19 CART Haematological malignancy

58 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Novartis pipeline in Phase 1 (2 of 2) 36 lead indications Lead indication

Immunology, Hepatology, Dermatology Respiratory Disease Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) CEE321 CEE321 Pan JAK Inhibitor AD LTP001 LTP001 - Respiratory diseases DFV890 DFV890 - Anti-inflammatory therapy NCJ424 NCJ424 - Respiratory diseases FIA586 FIA586 - NASH MHS552 MHS552 - Autoimmune indications MHV370 MHV370 - Sjögren’s SLE NGI226 NGI226 - Tendinopathy Cardiovascular, Renal, Metabolism Code Name Mechanism Indication(s) Neuroscience MBL949 MBL949 - Obesity related diseases Code Name Mechanism Indication(s) OAV201 OAV201 (AVXS-201) MECP2 gene therapy Rett syndrome LMI070 branaplam mRNA splicing modulator Huntington

Ophthalmology Global Health Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) MHU650 MHU650 - Diabetic eye diseases KAF156 ganaplacide - Malaria prophylaxis

59 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Clinical Trials Update Includes selected ongoing or recently concluded global trials of Novartis development programs/products which are in confirmatory development or marketed (typically Phase 2b or later). For further information on all Novartis clinical trials, please visit: www.novartisclinicaltrials.com Cardiovascular, Renal and Metabolic Entresto® – Angiotensin II Receptor Neprilysin Inhibitor (ARNI)

Study NCT02678312 PANORAMA HF (CLCZ696B2319) NCT03785405 (CLCZ696B2319E1 – extension study) Indication Heart failure in pediatric patients Heart failure in pediatric patients Phase Phase 2 Phase 3 Patients 360 240 Primary Outcome Part 1: Pharmacodynamics and pharmacokinetics of Number of participants with Adverse Events (AEs) and Measures sacubitril/valsartan LCZ696 analytes Serious Adverse Events (SAEs) Part 2: Efficacy and safety compared with enalapril Arms/Intervention • Part 1: Sacubitril/valsartan 0.8 mg/kg or 3.1 mg/kg or both; • Single arm, open label sacubitril/valsartan (pediatric 0.4 mg/kg or 1.6 mg/kg or both (single doses). formulation granules (12.5, 31.25 mg in capsules); liquid • Part 2: enalapril/placebo 0.2 mg/kg bid (ped. formulation formulation (1mg/ml and 4mg/ml concentration) and 1mg/ml) and adult formulation (2.5, 5, 10 mg bid); adult formulation (50, 100, 200 mg bid)) Sacubitril/valsartan (LCZ696)/placebo: Ped. formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid) Target Patients Pediatric patients from 1 month to < 18 years of age with heart Pediatric patients with heart failure due to systemic left failure due to systemic left ventricle systolic dysfunction ventricle systolic dysfunction who have completed study CLCZ696B2319 Read-out Milestone(s) 2022; (Analysis of 110 pts from Part 2 formed the basis for 2022 pediatric submission in Apr-2019 and approval by the US FDA in Oct-2019 for the treatment of symptomatic HF with systemic left ventricular systolic dysfunction in children aged 1 year and older) Publication TBD TBD

62 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Entresto® – Angiotensin II Receptor Neprilysin Inhibitor (ARNI)

Study NCT02884206 PERSPECTIVE (CLCZ696B2320) NCT02468232 PARALLEL-HF (CLCZ696B1301) Indication Heart failure Heart failure, reduced ejection fraction Phase Phase 3 Phase 3 Patients 592 225 Primary Outcome Change from baseline in the CogState Global Cognitive Time to the first occurrence of the composite endpoint – either Measures Composite Score (GCCS) cardiovascular (CV) death or heart failure (HF) hospitalization • Sacubitril/valsartan 50, 100, and 200 mg bid with placebo • Sacubitril/valsartan 50 mg, 100 mg, 200 mg bid/placebo of of valsartan enalapril Arms/Intervention • Valsartan 40, 80, and 160 mg bid tablets with placebo for • Enalapril 2.5 mg, 5 mg, 10 mg bid / placebo of sacubitril/valsartan sacubitril/valsartan Patients with chronic heart failure with preserved ejection Japanese heart failure patients (NYHA Class II-IV) with Target Patients fraction reduced ejection fraction Read-out Milestone(s) 2022 Primary: Q1-2019 (actual); Extension (open-label): H1-2021 Publication TBD Submitted for Q4-2020: Primary manuscript in Circ J

63 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Entresto® – Angiotensin II Receptor Neprilysin Inhibitor (ARNI)

Study NCT01920711 PARAGON-HF (CLCZ696D2301) NCT03066804 PARALLAX (CLCZ696D2302) Indication Heart failure, preserved ejection fraction Heart failure, preserved ejection fraction Phase Phase 3 Phase 3 Patients 4,822 2,572 Cumulative number of primary composite events of Change in NT-proBNP from baseline to week 12 Primary Outcome cardiovascular (CV) death and total (first and recurrent) HF and change in 6 minute walk distance (6MWD) from baseline Measures hospitalizations to Week 24 • Sacubitril/valsartan 50 mg, 100 mg and 200 mg bid and • Sacubitril/valsartan or placebo 50 mg, 100 mg, and 200 mg matching placebo Arms/Intervention bid • Enalapril 2.5 mg, 5 mg and 10 mg bid and matching placebo • Valsartan or placebo 40 mg, 80 mg, and 160 mg bid • Valsartan 40 mg, 80 mg, 160 mg bid and matching placebo Heart failure patients (NYHA Class II-IV) with preserved Heart failure patients (NYHA Class II-IV) with preserved Target Patients ejection fraction ejection fraction Read-out Milestone(s) 2019 (actual) 2019 (actual) • Sep-2019: Primary manuscript (ARNI in HFpEF. Solomon S et al; NEJM. DOI: 10.1056/NEJMoa1908655) • Study design (Wachter et al; ESC-HF), May-2020 • Mar-2020: Published (NTproBNP, putative placebo analysis) • Primary data presented at ESC latebreaker, Aug-2020 Publication • Jun-2020: Submitted (renal outcomes, cognitive function) • Baseline data publication in EJHF (expected publication Q4- • Q4-2020 Planned: Urgent HF visits, regional differences, 2020), accepted Sep-2020 win ratio, adjudicated vs reported endpts; Subgroups (mode • Planned Primary Publication High Tier Journal in H1-2021 of death, MRA, age, gender)

64 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Entresto® – Angiotensin II Receptor Neprilysin Inhibitor (ARNI)

Study NCT02924727 PARADISE-MI (CLCZ696G2301) Indication Post-acute myocardial infarction Phase Phase 3 Patients 5,670

Time to the first occurrence of a confirmed composite Primary Outcome endpoint (cardiovascular (CV) death, heart failure (HF) Measures hospitalization, or outpatient heart failure)

• Sacubitril/valsartan 50 mg, 100 mg, 200 mg bid; placebo for ramipril ; placebo for valsartan Arms/Intervention • Ramipril 1.25 mg, 2.5 mg, and 5 mg bid; placebo for sacubitril/valsartan; placebo for valsartan

Post-AMI patients with evidence of LV systolic dysfunction Target Patients and/or pulmonary congestion, with no known prior history of chronic HF

Read-out Milestone(s) H1-2021 • Q4-2020 – Planned: PARADISE-MI study design / baseline characteristics Publication • Planned primary data presentation and publication in H2- 2021

65 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation KJX839 – siRNA (regulation of LDL-C)

Study NCT03060577 ORION-3 (CKJX839A12201E1) NCT03705234 ORION-4 (CKJX839B12301) Hypercholesterolemia inc. Atherosclerotic Cardiovascular Hypercholesterolemia inc. Heterozygous Familial Indication Disease (ASCVD) and ASCVD risk equivalents Heterozygous Hypercholesterolaemia (HeFH) Familial Hypercholesterolaemia (HeFH) Phase Phase 2 Phase 3 Patients 490 ~15,000 A composite of major adverse cardiovascular events, defined as: LDL-C reduction at Day 210 for Group 1 subjects • Coronary heart disease (CHD) death; Primary Outcome Changes in other lipids and lipoproteins and reduction of LDL- • Myocardial infarction; Measures C of more than 50% for patients that are above LDL-C goal ; • Fatal or non-fatal ischaemic stroke; or longer term exposure and safety. • Urgent coronary revascularization procedure Arm 1: every 6 month treatment KJX839 300mg (given by • Group 1 – inclisiran 300mg sc on Day 1 and every 180 days subcutaneous injection on the day of randomization, at 3 months thereafter for up to 4 years. and then every 6-months) for a planned median duration of • Group 2- Evolocumab 140mg s.c. injection on Day 1 and Arms/Intervention about 5 years every 2 weeks until Day 336, followed by inclisiran 300mg Arm 2: matching placebo (given bysubcutaneous injection on the on Day 360, Day 450 and then every 6 months for a day of randomization, at 3 months and then every 6- planned duration of 4 years. months) for a planned median duration of about 5 years. Patients with HeFH or pre-existing atherosclerotic Patient population with mean baseline LDL-C ≥ 100mg/dL Target Patients cardiovascular disease (ASCVD) on background statin +/- ezetimibe therapy Read-out Milestone(s) 2022 2025 Publication TBD TBD

66 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation KJX839 – siRNA (regulation of LDL-C)

Study NCT03851705 ORION-5 (CKJX839A12302) NCT03814187 ORION-8 (CKJX839A12305B) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolemia inc. Homozygous Familial Indication Hypercholesterolaemia (HeFH) and Homozygous Familial Hypercholesterolemia (HoFH) Hypercholesterolemia (HoFH) Phase Phase 3 Phase 3 Patients 56 randomized 2:1 (inclisiran: placebo) 2,991 entered the study • Proportion of subjects achieving prespecified low density Primary Outcome • LDL-C reduction at Day 150 lipoprotein cholesterol (LDL-C) targets at end of study Measures • Changes in PCSK9, other lipids and lipoproteins • Safety and tolerability profile of long term use of inclisiran • Part 1: inclisiran 300mg on Day 1 and Day 90 or placebo Inclisiran 300mg on day 1 (placebo patients entered into study on Day 1 and Day 90 from ORION 9, 10 & 11) or placebo on Day 1 (inclisiran • Part 2: inclisiran on Day 180 for patients who were patients entered into study from ORION 9, 10 & 11) then Arms/Intervention randomized to the placebo group only, inclisiran on Day inclisiran 300mg on Day 90 and every 6 months for a planned 270 and then every 6 months for a planned duration of 2 duation of 3 years years for all patients Patients with HeFH or pre-existing atherosclerotic Patients with HoFH with background statin +/- ezetimibe cardiovascular disease (ASCVD) on background statin +/- Target Patients therapy ezetimibe therapy and risk equivalents (patients from ORION 9, 10 & 11 studies) Read-out Milestone(s) Primary: Q3-2020 (actual); Final: H2-2021 2023 Publication TBD TBD

67 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation LNP023 – Factor B inhibition of the complement alternative pathway

Study NCT03373461 (CLNP023X2203) NCT04154787 (CLNP023D12201) Indication IgA nephropathy (IgAN) Idiopathic membranous nephropathy (iMN) Phase Phase 2 Phase 2 Patients 112 72

Primary Outcome Change from baseline of log transformed UPCR derived from Change from baseline of UPCR derived from 24hr urine Measures the 24h urine collections at Baseline and Day 90 collections at Baseline and Week 24

• Placebo • LNP023 Dose 1 – 10mg bid • LNP023 Dose – 200mg bid Arms/Intervention • LNP023 Dose 2 – 50mg bid • LNP023 Dose – 50mg bid • LNP023 Dose 3 – 200mg bid • Rituximab • LNP023 Dose 4 – 100mg bid (Part 2 only)

Patients with biopsy proven iMN who are at high risk of Target Patients Patients with biopsy-verified IgA nephropathy disease progression defined on the basis of antibody anti- PLA2R titre and proteinuria

Read-out Milestone(s) H1-2021 (IA) 2022

Publication TBD TBD

68 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation LNP023 – Factor B inhibition of the complement alternative pathway

Study NCT03832114 (CLNP023X2202) NCT03955445 (CLNP023B12001B) Indication C3 glomerulopathy (C3G) C3 glomerulopathy (C3G)

Phase Phase 2 Phase 2 (open-label extension)

27 patients from ongoing Ph2 (sample size from Ph3 pending Patients 27 HA discussions Q1 2021), total patients for this study will increase Cohort A: Ratio to Baseline of UPCR to Week 12 derived from Characterize the effect of LNP023 treatment on a composite 24hr urine collection Primary Outcome renal response endpoint at 9 months (1. a stable or improved Cohort B: Change from Baseline in C3 Deposit Score (based Measures eGFR and, 2. a reduction in proteinuria and 3. an increase in on immunofluorescence microscopy) at Week 12 C3 compared to the CLNP023X2202 baseline visit)

Increasing doses of LNP023 up to 200mg bid: Arms/Intervention • Cohort A: Native kidney patients • Open-label LNP023 200mg bid • Cohort B: Kidney transplanted patients

Target Patients Patients with C3 glomerulopathy Patients with C3 glomerulopathy Read-out Milestone(s) H1-2021 2024 Interim analysis data from Cohort-A presented at American Publication TBD Society of Nephrology (ASN 2020)

69 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation LNP023 – Factor B inhibition of the complement alternative pathway

Study NCT03439839 (CLNP023X2201) NCT03896152 (CLNP023X2204) Indication Paroxysmal nocturnal hemoglobinuria (PNH) Paroxysmal nocturnal hemoglobinuria (PNH) Phase Phase 2 Phase 2 Patients 16 13 Reduction of PNH associated hemolysis, based on Primary Outcome Reduction of chronic hemolysis, based on LDH level at Week percentage of patients with 60% reduction in LDH or LDH Measures 13 below upper limit of normal up to 12 weeks of treatment. • Cohort 1: 10 patients receiving LNP023 200mg bid, in addition to SoC, for 13 weeks with 3yr treatment extension • Arm 1: 4wks treatment LNP023 25mg bid followed by 8wk period treatment LNP023 100mg bid and 2yr extension LNP023 • Cohort 2: 5 patients receiving LNP023 50mg bid, in addition 100mg bid Arms/Intervention to SoC, for minimum 2 weeks with 3yr treatment extension • Arm 2: 4wks treatment LNP023 50mg bid followed by 8wk period. Dose may be increased D15 onwards to 200mg bid treatment LNP023 200mg bid and 2yr extension LNP023 if LDH not within limit of normal or reduced by at least 60% 200mg bid compared to Baseline. Patients with PNH, showing signs of active hemolysis despite Patients with PNH, showing signs of active hemolysis, not Target Patients treatment with SoC (defined as an antibody with anti C5 treated with any other complement inhibitor less than 3 activity). months prior to study start Day 1 Primary: Q2-2020 (actual) Primary: Q2-2020 (actual) Read-out Milestone(s) Extension: 2023 Extension: 2022 Antonio M. Risitano, MD, PhD1 et al. Presented at EBMT Publication TBD 2020 congress

70 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation TQJ230 – Antisense oligonucleotide targeting apolipoprotein(a) mRNA

Study NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Indication Cardiovascular risk reduction Phase Phase 3 Patients 7,680

Time to the first occurrence of MACE (cardiovascular death, Primary Outcome non-fatal MI, non-fatal stroke and urgent coronary re- Measures vascularization)

TQJ230 80 mg injected monthly subcutaneously or matched Arms/Intervention placebo

Patients with a history of Myocardial infarction or Ischemic Target Patients Stroke, or a clinically significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL

Read-out Milestone(s) 2024 Publication TBD

71 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Immunology, Hepatology & Dermatology CFZ533 – Blocking, non-depleting, Fc-silent, anti-CD40 monoclonal antibody

Study NCT03663335 CIRRUS I (CCFZ533A2201) NCT03905525 TWINSS (CCFZ533B2201)

Indication Kidney transplantation Sjögren's syndrome

Phase Phase 2 Phase 2

Patients 681 260

Cohorts 1 and 2-mean iBox risk prediction score at 12 months. Change in EULAR Sjögren’s syndrome Disease Activity Index Primary Outcome Integrative score that will provide a prediction of graft survival (ESSDAI) score and EULAR Sjögren’s syndrome Patient Measures at year 5 Reported Index (ESSPRI) score • Two cohorts: de novo TX and maintenance • Three dose arms of CFZ533 Arms/Intervention • Test Arms: CFZ533 + MMF + corticosteroids • Placebo • Standard of Care: TAC + MMF + corticosteroids Target Patients Kidney transplant recipients Patients with Sjögren's syndrome

Read-out Milestone(s) 2022 2022

Publication TBD TBD

73 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation CFZ533 – Blocking, non-depleting, Fc-silent, anti-CD40 monoclonal antibody

Study NCT03781414 CONTRAIL I (CCFZ533A2202)

Indication Liver transplantation

Phase Phase 2

Patients 128

Primary Outcome Proportion of patients with composite event (BPAR, Graft Loss Measures or Death) over 12 months

• Control/Standard of Care: TAC + MMF + Corticosteroids Arms/Intervention • CFZ533 dose A + MMF + Corticosteroids • CFZ533 dose B + MMF + Corticosteroids Target Patients Liver transplant recipients

Read-out Milestone(s) 2023

Publication TBD

74 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Cosentyx® – Anti IL-17

Study NCT03504852 (CAIN457A2324) NCT03589885 MATURE (CAIN457A2325) Indication Psoriasis Psoriasis Phase Phase 3B Phase 3 Patients 331 122

Primary Outcome PASI 90 response and IGA mod 2011 0 or 1 response after 16 PASI 75 response and IGA mod 2011 0 or 1 response after 12 Measures weeks of treatment weeks of treatment

• Secukinumab 300 mg every 2 weeks after weekly doses till • Secukinumab 2 mL (300 mg) auto-injector Week 4 • Secukinumab 2 x 1 mL (150 mg each) prefilled syringe Arms/Intervention • Secukinumab 300 mg every 4 weeks after weekly doses till • Placebo 2 mL auto-injector Week 4 • Placebo 2 x 1 mL prefilled syringe Target Patients Subjects (≥90kg) with moderate to severe plaque psoriasis Subjects with moderate to severe plaque psoriasis Read-out Milestone(s) Q3-2020 (actual) Final: Q4-2020 (actual) Publication Publication (primary efficacy) planned in H1-2021 Publication (16 week primary results) planned in H1-2021

75 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Cosentyx® – Anti IL-17

Study NCT02471144 (CAIN457A2310) NCT03668613 (CAIN457A2311) Indication Psoriasis Psoriasis Phase Phase 3 Phase 3 Patients 162 84 Psoriasis Area and Severity Index (PASI) 75 response and Psoriasis Area and Severity Index (PASI) 75 response and Primary Outcome Investigators' Global Assessment (IGA) 0 or 1 response at Investigators' Global Assessment (IGA) 0 or 1 response at Measures week 12 week 12 • Secukinumab low dose • Secukinumab high dose • Secukinumab low dose Arms/Intervention • Placebo • Secukinumab high dose • Etanercept (comparator) Patients from 6 to less than 18 years of age with severe Pediatric patients of age 6 to <18 years, with moderate to Target Patients chronic plaque psoriasis severe plaque psoriasis Read-out Milestone(s) 2023 2023 Publication Published Q4 2020 JEADV Publication planned in H1-2021

76 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Cosentyx® – Anti IL-17

Study NCT03066609 (CAIN457A2318) Indication Psoriasis Phase Phase 3 Patients 543 Psoriasis Area and Severity Index (PASI) 75 response and Primary Outcome Investigators' Global Assessment (IGA) 0 or 1 response at Measures week 12 • Secukinumab 300 mg Arms/Intervention • Secukinumab 150 mg • Placebo

Patients with moderate to severe chronic plaque-type Target Patients psoriasis with or without psoriatic arthritis comorbidity

Read-out Milestone(s) Q1-2019 (actual) • Week 16 results: Poster presented at: 2019 American Academy of Dermatology (AAD) Annual Meeting, • March 1–5, 2019, Washington, D.C. Publication • 52-week results: Poster at EADV 2019, Madrid 9-13 October, 2019 • Manuscript publication H1-2021

77 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Cosentyx® – Anti IL-17

Study NCT03031782 (CAIN457F2304) NCT03769168 (CAIN457F2304E1 – extension study) Indication Psoriatic arthritis Psoriatic arthritis Phase Phase 3 Phase 3 Patients 80 64

Primary Outcome Time to 33 flares Number of participants with JIA ACR30 response Measures

• Secukinumab (pre-filled syringe) 75 mg • Secukinumab 75 mg/0.5 ml Arms/Intervention • Placebo • Secukinumab 150 mg/1.0 ml

Juvenile idiopathic arthritis subtypes of psoriatic and enthesitis- Patients with juvenile idiopathic arthritis subtypes of juvenile Target Patients related arthritis psoriatic arthritis and enthesitis related arthritis Read-out Milestone(s) H1-2021 2025 Publication Planned publication in 2021 TBD

78 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Cosentyx® – Anti IL-17

Study NCT02696031 PREVENT (CAIN457H2315) NCT03259074 SURPASS (CAIN457K2340) Indication Non-radiographic axial spondyloarthritis Ankylosing spondylitis Phase Phase 3 Phase 3 Patients 555 837 The proportion of participants who achieved an ASAS 40 Primary Outcome No radiographic structural progression as measured by response (Assessment of SpondyloArthritis International Measures modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Society criteria); • Secukinumab 150 mg load • Secukinumab 150/300 mg Arms/Intervention • Secukinumab 150 mg no load • Adalimumab biosimilar 40 mg • Placebo Target Patients Patients with non-radiographic axial spondyloarthritis Patients with active ankylosing spondylitis Read-out Milestone(s) Week 52: Q3-2019 (actual); Final: H1-2021 2022 • Abstract (16 week results) presented at ACR 2019 • Abstract (52 week results) presented at EULAR 2020 • Study design manuscript published. Baraliakos et al. Clinical Publication • Manuscript published in Aug 2020 in Arthritis and Drug Investigation (2020) 40:269–278. Rheumatology • Further publications planned

79 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Cosentyx® – Anti IL-17

Study NCT03713619 SUNSHINE (CAIN457M2301) NCT04179175 (CAIN457M2301E1) Indication Hidradenitis Suppurativa (HS) Hidradenitis Suppurativa (HS) Phase Phase 3 Phase 3 Patients 471 745

Primary Outcome Proportion of participants with Hidradenitis Suppurativa clinical Proportion of patients with Hidradenitis Suppurativa Clinical Measures response (HiSCR) Response (HiSCR)

• Secukinumab 300 mg every 2 weeks • Secukinumab 300 mg every 4 weeks • Secukinumab 300 mg every 2 weeks Arms/Intervention • Placebo (every 2 weeks) • Secukinumab 300 mg every 4 weeks • Placebo (every 4 weeks) Patients with moderate to severe hidradenitis suppurativa Target Patients Patients with moderate to severe Hidradenitis Suppurativa completing either of the core trials AIN457M2301 (NCT 0313632) or AIN567M2302 (NCT03713619) Read-out Milestone(s) Primary (week 16): H2-2021; Final: 2022 2025 Publication Study design SHSA 2020; Primary 2022 Study design SHSA 2020

80 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Cosentyx® – Anti IL-17

Study NCT03713632 SUNRISE (CAIN457M2302) Indication Hidradenitis Suppurativa (HS) Phase Phase 3 Patients 471

Primary Outcome Proportion of patients with Hidradenitis Suppurativa Clinical Measures Response (HiSCR)

• Secukinumab 300 mg every 2 weeks • Secukinumab 300 mg every 4 weeks Arms/Intervention • Placebo (every 2 weeks) • Placebo (every 4 weeks) Target Patients Subjects with moderate to severe Hidradenitis Suppurativa Read-out Milestone(s) Primary (week 16): H2-2021; Final: 2022 Publication StudStudy design SHSA 2020; Primary 2022

81 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Cosentyx® – Anti IL-17

Study NCT04156620 INVIGORATE-1 (CAIN457P12301) NCT04209205 INVIGORATE-2 (CAIN457P12302) Indication Axial spondyloarthritis Psoriatic Arthritis (PsA) Phase Phase 3 Phase 3 Patients 500 380

Primary Outcome The proportion of subjects achieving an ASAS40 (Assessment The proportion of subjects achieving American College of Measures of SpondyloArthritis International Society criteria) response Rheumatology 50 (ACR50) response criteria

• Secukinumab intravenous (i.v.) regimen • Secukinumab intravenous (i.v.) regimen Arms/Intervention • Placebo intravenous (i.v.) regimen • Placebo intravenous (i.v.) regimen

Patients with active psoriatic arthritis (PsA) despite current or Target Patients Patients with active axial spondyloarthritis previous NSAID, DMARD and/or anti-TNF therapy

Read-out Milestone(s) Primary (week 16): 2022; Final: 2023 2022 Publication TBD TBD

82 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Cosentyx® – Anti IL-17

Study NCT04181762 SELUNE (CAIN457Q12301) NCT04300296 PRELUDE (CAIN457S12201) Indication Lupus Nephritis Lichen Planus Phase Phase 3 Phase 2 Patients 460 108 Proportion of patients achieving Investigator’s Global Primary Outcome Proportion of subjects achieving protocol-defined CRR Assessment (IGA 0/1) score at 16 weeks +30% delta vs Measures placebo

• Secukinumab 300 mg s.c. • Secukinumab 300 mg s.c. Arms/Intervention • Placebo s.c. • Placebo s.c.

Patients with active lupus nephritis (ISN/RPS Class III or IV, Adult patients with biopsy-proven lichen planus not adequately Target Patients with or without co-existing class V features) controlled by topical therapies Read-out Milestone(s) 2026 2022 Publication TBD TBD

83 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation LJC242 – FXR agonist + CCR2/CCR5 inhibitor

Study NCT03517540 TANDEM (CLJC242A2201J) Indication Non-alcoholic steatohepatitis Phase Phase 2 Patients 193

Evaluation of safety and tolerability of combination therapy Primary Outcome (tropifexor + cenicriviroc) by monitoring adverse event profile, Measures vital signs and laboratory parameters

• Arm A: tropifexor (LJN452) dose 1 • Arm B: cenicriviroc (CVC) Arms/Intervention • Arm C: LJN452 dose 1 + CVC • Arm D: LJN452 dose 2 + CVC Adult patients with non-alcoholic steatohepatitis (NASH) and Target Patients liver fibrosis Read-out Milestone(s) Q4-2020 Publication Abstract planned in H1-2021

84 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation LJN452 – FXR Agonist

Study NCT04065841 ELIVATE (CLJN452D12201C) Indication Non-alcoholic steatohepatitis (NASH) Phase Phase 2 Patients 380

Proportion of patients with resolution of NASH and no Primary Outcome worsening of fibrosis OR improvement in fibrosis by at least Measures one stage without worsening of NASH at Week 48 compared with baseline

• Arm A: combination therapy tropifexor + licogliflozin • Arm B: tropifexor monotherapytropifexor + licogliflozin placebo Arms/Intervention • Arm C: licogliflozin monotherapylicogliflozin + tropifexor placebo • Arm D: licogliflozin placebo + tropifexor placebo Adult patients with biopsy based non-alcoholic steatohepatitis Target Patients (NASH) and liver fibrosis Read-out Milestone(s) 2022

Publication Planned in H1-2023

85 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation LOU064 – Bruton's tyrosine kinase (BTK) inhibitor

Study NCT03926611 (CLOU064A2201) NCT04109313 (CLOU064A2201E1) Indication Chronic spontaneous urticaria (CSU) Chronic spontaneous urticaria (CSU) Phase Phase 2 Phase 2 Patients 308 250 Primary Outcome Change from baseline in weekly Urticaria Activity Score (UAS7) at Week 4 • Long-term safety and tolerability Measures • Arm 1 Low dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 • Arm 2 Medium dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 • Selected dose of LOU064 taken orally twice • Arm 3 High dose of LOU064 orally in the morning (once daily) and matching Arms/Intervention a day (morning and evening) from day 1 to placebo in the evening from Day 1 to 85 week 52 • Arm 4 Low dose of LOU064 orally, twice daily from Day 1 to 85 • Arm 5 Medium dose of LOU064 orally, twice daily from Day 1 to 85 • Arm 6 High dose of LOU064 orally, twice daily from Day 1 to 85 • Placebo arm Matching placebo, orally, twice daily from Day 1 to 85 Patients with CSU who have participated in Target Patients Adults with CSU inadequately controlled by H1-antihistamines preceding studies with LOU064 Read-out Milestone(s) H2-2021 2022 Primary resuls: EADV2021 synchronized with manuscript (NEJM), ACAAI2021 Publication TBD Secondary results: AAAAI, AAD 2022

86 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation QGE031 – Anti-IgE

Study NCT02477332 (CQGE031C2201) NCT02649218 (CQGE031C2201E1) Indication Chronic spontaneous urticaria Chronic spontaneous urticaria Phase Phase 2 Phase 2 Patients 382 226 Primary Outcome Establish dose-response relationship of QGE031 with respect Long-term safety; number of participants with treatment- Measures to achievement of complete hives response at week 12 emergent adverse events • Ligelizumab 24mg q4wks for 20 weeks • Ligelizumab 72mg q4wks for 20 weeks • Ligelizumab 240mg q4wks for 20 weeks Arms/Intervention Ligelizumab 240 mg q4wks open label for 52 weeks • Ligelizumab 120mg single dose • Omalizumab 300mg q4wks for 20 weeks • Placebo q 4wks for 20 weeks Adult patients with chronic spontaneous urticaria inadequately Adult patients with chronic spontaneous urticaria inadequately controlled with H -antihistamines at approved or increased controlled with H -antihistamines at approved or increased Target Patients 1 1 doses, alone or in combination with H2-antihistamines or doses, alone or in combination with H2-antihistamines or leukotriene receptor antagonists. leukotriene receptor antagonists. Read-out Milestone(s) 2017 (actual) 2019 (actual) • H1-2021 3 Manuscripts: Angioedema, Sleep/DLQI • H1-2021 manuscript: primary results extension trial (NEJM) (including also ext. data), Data visualization Publication • 2021 Congresses: exploratory data AAAAI, AAD, EAACI, • 2021 Congresses: exploratory data EAACI, EADV, ACAAI, EADV, ACAAI, encores at GUF encores at GUF

87 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation QGE031 – Anti-IgE

Study NCT03437278 (CQGE031C2202) NCT04210843 (CQGE031C2302E1) Indication Chronic spontaneous urticaria Chronic spontaneous urticaria Phase Phase 2 Phase 3 Patients 48 800 Primary Outcome The proportion of subjects with well-controlled disease Change in the 7 day Urticaria Activity Score (UAS7) Measures (UAS7 ≤ 6) at week 12 • Ligelizumab high dose q4wks for 24 weeks • Ligelizumab Dose 1 and 3 Arms/Intervention • Ligelizumab low dose q4wks for 24 weeks • Ligelizumab Dose 2 and 3 • Placebo / ligelizumab high dose q4wks for 8 / 16 weeks Adolescents from 12 to <18 years of age, with chronic Patients who completed studies CQGE031C2302, Target Patients spontaneous urticaria CQGE031C2303, CQGE031C2202 or CQGE031C1301 Read-out Milestone(s) H2-2021 2026

• Study design was presented at PAAM (Peds Allergy & Asthma Meeting) and at UCARE meeting 2019 • Baseline characteristics 2020/21 Publication Study design presented at 2020 EAACI • Primary results to be presented in late 2021/2022 (e.g. EAACI, PAAM, EADV) • Manuscript to be submitted in 2022

88 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation QGE031 – Anti-IgE

Study NCT03580369 Pearl 1 (CQGE031C2302) NCT03580356 Pearl 2 (CQGE031C2303) Indication Chronic spontaneous urticarial / Chronic idiopathic urticaria Chronic spontaneous urticarial / Chronic idiopathic urticaria Phase Phase 3 Phase 3 Patients 1,050 1,050

Primary Outcome Absolute change from baseline in UAS7 (Urticaria Activity Absolute change from baseline in UAS7 (Urticaria Activity Measures Score) at week 12 Score) at week 12

• Ligelizumab dose A q4w for 52 weeks • Ligelizumab dose A q4w for 52 weeks • Ligelizumab dose B q4w for 52 weeks • Ligelizumab dose B q4w for 52 weeks Arms/Intervention • Omalizumab 300 mg q4w for 52 weeks • Omalizumab 300 mg q4w for 52 weeks • Placebo q4w from randomization to wk20, then ligelizumab • Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria Adolescents and adults with chronic spontaneous urticaria Target Patients inadequately controlled with H1-antihistamines inadequately controlled with H1-antihistamines Read-out Milestone(s) H2-2021 H2-2021 • Study design presented at UCARE 2018 Publication • Primary results to be presented in 2022 (e.g. EAACI, PAAM, EADV) • Manuscript to be submitted in 2022

89 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation VAY736 – Fully human IgG1/κ anti-BAFF-R mAb

Study NCT02962895 (CVAY736A2201) NCT03217422 AMBER (CVAY736B2201) Indication Primary Sjögren's syndrome Autoimmune hepatitis Phase Phase 2 Phase 2 Patients 180 80

Primary Outcome Safety and efficacy of VAY736 in primary Sjögren's syndrome Alanine aminotransferase (ALT) normalization Measures (pSS)

• VAY736 • VAY736 Arms/Intervention • Placebo • Placebo control with conversion to active VAY736

Patients with moderate to severe primary Sjögren's syndrome Autoimmune hepatitis patients with incomplete response or Target Patients (pSS) intolerant to standard treatment of care

Read-out Milestone(s) Q2-2020 (actual) 2026 Publication • Manuscript Q4-2020 TBD

90 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Neuroscience Aimovig® – CGRP receptor antagonist

Study NCT03096834 LIBERTY (CAMG334A2301) NCT03333109 EMPOWER (CAMG334A2302) Indication Migraine Migraine Phase Phase 3 Phase 3 Patients 246 900

Primary Outcome Percentage of patients with a 50% response in the reduction Change from baseline in monthly migraine days at the last Measures of Monthly Migraine Days (MMD) month (Month 3) of the double-blind treatment period

• AMG334 (erenumab) Dose 1 • Subcutaneous injection of AMG334 (erenumab) Arms/Intervention • AMG334 (erenumab) Dose 2 • Subcutaneous injection of placebo • Placebo

Adult episodic migraine patients who have failed prophylactic Target Patients Adult episodic migraine patients migraine treatments

Double-blind: 2017 (actual); Read-out Milestone(s) Q1-2020 (actual) Extension (open-label): H1-2021 • PROs and prespecified subgroup analysis (Double-blind phase) submitted to JNNP accepted Aug-2020 • Primary analysis manuscript submitted end 2020 • Submitted May 28, 2020 1 year Open-label extension to • Abstracts accepted for MTIS in 2020 Publication Neurology • Secondary analysis to be submitted to multiple congresses • Planned for Q4-2020: 2Y Open-label extension Abstracts in 2021 completed for EAN, AHS, EHF and MTIS in 2020

92 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Aimovig® – CGRP receptor antagonist

Study NCT03867201 DRAGON (CAMG334A2304) Indication Migraine Phase Phase 3 Patients 550

Primary Outcome Change from baseline in monthly migraine days during the last Measures 4 weeks of the 12-week treatment period

• Subcutaneous injection of AMG334 (erenumab) 70 mg Arms/Intervention • Subcutaneous injection of placebo

Target Patients Adult chronic migraine patients

Double-blind:2021; Read-out Milestone(s) Extension (open-label): 2024

Planned in H2-2022 for double-blind phase and H1-2025 for Publication open-label extension phase

93 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation LMI070 – SMN2 RNA splice modulator

Study NCT02268552 (CLMI070X2201) Indication Type 1 spinal muscular atrophy Phase Phase 1/2 Patients 39

Primary Outcome Number of participants with adverse events (AEs), serious Measures adverse events (SAEs) and deaths

Branaplam oral, once weekly: • Part 1: 5 ascending doses Arms/Intervention • Part 2: 2 different dose levels • Part 3: patients continue on initial dose assigned in Part 1 or Part 2 Target Patients Patients with type 1 spinal muscular atrophy

Study Part 2: Q3-2020 (actual) Read-out Milestone(s) Study Part 3: 2023

Publication TBD

94 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation OMB157 – Anti-CD20

Study NCT03249714 APOLITOS (COMB157G1301) NCT03650114 ALITHIOS (COMB157G2399) Indication Multiple sclerosis Multiple Sclerosis Phase Phase 2 Phase 3 Patients 60 2010

Reduced cumulative number of Gd-enhanced T1 lesions Evaluate the long-term safety and tolerability of ofatumumab Primary Outcome across 4 MRI scans at week 12, 16, 20 and 24 (ofatumumab 20 mg subcutaneous (sc) once every 4 (q4) weeks in subjects Measures vs placebo) with RMS from the first dose of ofatumumab

• Ofatumumab 20 mg subcutaneous injections Arms/Intervention • Ofatumumab 20 mg every 4 weeks • Placebo

Target Patients Patients with relapsing forms of multiple sclerosis Patients with relapsing MS Read-out Milestone(s) Q1-2020 (actual) 2028 Publication Publication planned for H1-2021 TBD

95 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Zolgensma® – SMN1 gene replacement therapy

Study NCT03461289 STRIVE-EU (CL-302) NCT03306277 STRIVE (CL-303) Indication Type 1 spinal muscular atrophy Type 1 spinal muscular atrophy Phase Phase 3 Phase 3 Patients 33 22

Primary Outcome • Achievement of independent sitting for at least 30 seconds Proportion of participants sitting without support Measures • Event-free survival

Arms/Intervention Open-label, single-arm, single-dose, intravenous Open-label, single-arm, single-dose, intravenous Target Patients Patients with spinal muscular atrophy Type 1 Patients with Spinal Muscular Atrophy Type 1

Read-out Milestone(s) Q4-2020 (actual) Q4-2019 (actual) Final results at the 2021 annual meeting of the Publication of full results in top-tier neurology journal in Publication European Academy of Neurology (EAN, June 19‒22) February 2021

96 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Zolgensma® – SMN1 gene replacement therapy

Study NCT03505099 SPR1NT (CL-304) NCT03837184 STR1VE Asia Pacific (CL-306) Indication Spinal muscular atrophy Type 1 spinal muscular atrophy Phase Phase 3 Phase 3 Patients 30 2 • [2 copies of SMN2] Percentage of participants achieving functional independent sitting for at least 30 seconds at any Primary Outcome visit Proportion of participants sitting without support Measures • [3 copies of SMN2] Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit Arms/Intervention Open-label, single-arm, single-dose, intravenous Open-label, single-arm, single-dose, intravenous Pre-symptomatic patients with spinal muscular atrophy and Target Patients Patients with spinal muscular atrophy Type 1 multiple copies SMN2 Read-out Milestone(s) H2-2021 H2-2021 (Muscular Dystrophy Association) MDA 2021 (March 15‒18) Publication and (American Academy of Neurology) AAN 2021 TBD (April 17‒22)

97 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Zolgensma® – SMN1 gene replacement therapy

Study NCT03381729 STRONG (CL-102) Indication Type 2 spinal muscular atrophy Phase Phase 1 Patients 51

• Safety and tolerability, incidence of adverse events Primary Outcome • Proportion of patients achieving Standing Milestone Measures • Change in Hammersmith Functional Motor Scale

Arms/Intervention Open-label, single-arm, single-dose, intrathecal Target Patients Patients with spinal muscular atrophy with 3 copies of SMN2 Read-out Milestone(s) Cohort B: Q4-2019 (actual); Cohort C1: TBC Publication TBD

1 FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study

98 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Oncology ABL001 – Specific, allosteric Bcr-Abl kinase inhibitor

Study NCT03106779 ASCEMBL (CABL001A2301) Indication Chronic myeloid leukaemia (CML) Phase Phase 3 Patients 233

Primary Outcome Major Molecular Response (MMR) rate at 24 weeks Measures

• ABL001 40 mg bid Arms/Intervention • Bosutinib 500 mg

Patients with chronic myelogenous leukemia in chronic phase, Target Patients previously treated with 2 or more tyrosine kinase inhibitors

Read-out Milestone(s) Q3-2020 (actual) • Hochhaus A., et al. [Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib Publication (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs), LBA-4] ASH 2020 • Manuscript submission Q4-2020

100 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation ACZ885 – IL-1β inhibitor

Study NCT03447769 CANOPY-A (CACZ885T2301) NCT03631199 CANOPY-1 (CACZ885U2301) Indication Adjuvant NSCLC 1st Line Non-small cell lung cancer (NSCLC) Phase Phase 3 Phase 3 Patients 1,500 627 • Safety run-in part: Incidence of dose limiting toxicities Primary Outcome Disease free survival (primary), overall survival (key • Double-blind, randomized, placebo-controlled part: Measures secondary) Progression free survival (PFS) • Overall survival (OS) • Canakinumab 200mg q3w sc for 18 cycles • Canakinumab or matching placebo in combination with Arms/Intervention • Placebo q3w sc for 18 cycles pembrolizumab and platinum-based doublet chemotherapy

Patients with: Patients with • High–risk NSCLC (AJCC/UICC v.8 stage II-IIIA and IIIB • Histologically confirmed Stage IIIB, IV NSCLC with no prior Target Patients (T>5cm N2)) after complete resection and standard of care systemic anticancer therapy adjuvant cisplatin-based chemotherapy • Squamous and non-squamous NSCLC • All histologies • No EGFR mutation and ALK rearrangement Read-out Milestone(s) 2023 H2-2021 • Johnson B et al. Presented at AACR-NCI-EORTC 2019 (safety run-in) Publication TBD • Manuscript submission Q4-2020 • Abstract submission to congress H1-2021

101 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation ACZ885 – IL-1β inhibitor

Study NCT03626545 CANOPY-2 (CACZ885V2301) Indication 2nd / 3rd Line Non-small cell lung cancer (NSCLC) Phase Phase 3 Patients 240 • Safety run-in part: Incidence of dose limiting toxicities Primary Outcome • Double-blind, randomized, placebo-controlled part: Overall Measures Survival

• Canakinumab in combination with docetaxel Arms/Intervention • Canakinumab matching-placebo in combination with docetaxel

Patients with: • Stage IIIB or IV NSCLC without EGFR, ALK, ROS-1 or B- Target Patients RAF mutation • Previously treated with platinum therapy and PD(L)1-inhibitor

Read-out Milestone(s) H1-2021 Publication Abstract submission to congress H1-2021

102 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation BYL719 – Alpha-specific PI3K inhibitor

Study NCT04208178 EPIK-B2 (CBYL719G12301) NCT04251533 EPIK-B3 (CBYL719H12301)

Indication HER-2 positive breast cancer Triple negative breast cancer Phase Phase 3 Phase 3 Patients 548 566

Primary Outcome Progression-free Survival (PFS) for patients with PIK3CA Progression-free survival (PFS) Measures mutant status

• Alpelisib + trastuzumab + pertuzumab • Alpelisib 300 mg + nab-paclitaxel 100 mg/m² Arms/Intervention • Trastuzumab + pertuzumab • Placebo + nab-paclitaxel 100 mg/m²

Patients with advanced triple negative breast cancer with Patients with HER2-positive advanced breast cancer with a either Phosphoinositide-3-kinase Catalytic Subunit Alpha Target Patients PIK3CA mutation (PIK3CA) mutation or Phosphatase and Tensin Homolog Protein (PTEN) loss without PIK3CA mutation

Read-out Milestone(s) 2025 2023

Publication TBD TBD

103 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation INC280 – MET Inhibitor

Study NCT02414139 (CINC280A2201) NCT04427072 (CINC280A2301) EGFR Wild-type, ALK negative advanced Non-small Cell Lung Indication Non-small cell lung cancer Cancer (NSCLC) Phase Phase 2 Phase 2 Patients 364 90 Primary Outcome Progression free survival (PFS) per blinded independent review Overall Response Rate (ORR) Measures committee (BIRC) using RECIST v1.1 • Pre-treated pts. with MET GCN: ≥ 6; ≥ 4 and < 6; < 4 • Pre-treated pts. with MET mutations regardless of cMET • Arm 1: 400mg of capmatinib tablets administered orally twice GCN as second or third line daily Arms/Intervention • Treatment-naïve pts. with MET dysregulation • Arm 2: Docetaxel 75 mg/m2 by intravenous infusion every 21 • Pre-treated pts with MET dysregulation – second line days • Treatment-naïve pts with cMET mutations regardless of cMET GCN Adult patients with EGFR wild-type (wt), ALK-negative Previously Treated Patients With EGFR wt, ALK Negative, Target Patients advanced/ metastatic NSCLC with either MET amplification or Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC MET mutations Harboring MET Exon 14 Skipping Mutation (METΔex14). Read-out Primary 2022 2019 (actual) Milestone(s) Final: 2024 • Wolf J, et al. Presented at ASCO 2019 • Wolf J, et al. Presentation at ASCO 2020 (cohort 1 and 5a) Publication • TBD • Groen H, et al. Presentation at ASCO 2020 (cohort 6) • Wolf J, et al. N Engl J Med 2020; 383:944-957

104 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Jakavi® – JAK1/2 inhibitor

Study NCT03112603 REACH3 (CINC424D2301) NCT03491215 REACH4 (CINC424F12201) Indication Steroid-refractory chronic graft vs. host disease (SR cGVHD) Acute graft versus host disease Phase Phase 3 Phase 2 Patients 330 45 Primary Outcome • Measurement of PK parameters Overall Response Rate (ORR) at 183 Days Measures • Overall Response Rate (ORR)

• Ruxolitinib 10mg bid Arms/Intervention • Ruxolitinib • Best available therapy (BAT)

Pediatric patients with grade II-IV acute graft vs. host disease Target Patients Patients with SR cGVHD after allogeneic hematopoietic stem cell transplantation Read-out Milestone(s) Final: Q3-2020 (actual) 2023 • Manuscript submission in H1-2021 Publication • REACH3 primary analysis oral presentation at ASH TBD (American Society of Hematology) 2020

105 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Jakavi® – JAK1/2 inhibitor

Study NCT03774082 REACH5 (CINC424G12201) NCT04097821 ADORE (CINC424H12201) Indication Chronic graft versus host disease Myelofibrosis Phase Phase 2 Phase 1/2 Patients 42 130

Primary Outcome • Incidence of dose limiting toxicities within the first 2 cycles • Overall Response Rate (ORR) Measures • Response rate at the end of cycle 6 • Ruxolitinib • Ruxolitinib+Siremadlin Arms/Intervention • Ruxolitinib 5mg tablets / pediatric formulation • Ruxolitinib+Crizanlizumab • Ruxolitinib+MBG453 Pediatric subjects with moderate and severe chronic Graft vs. Target Patients Patients with Myelofibrosis (MF) Host disease after allogeneic stem cell transplantation

Read-out Milestone(s) 2027 2024 Publication TBD TBD

106 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Kisqali® – CDK 4/6 inhibitor

Study NCT03701334 NATALEE (CLEE011O12301C)

Adjuvant treatment of hormone receptor (HR)-positive, HER2- Indication negative, early breast cancer (EBC)

Phase Phase 3 Patients ~5,000 Invasive Disease-Free Survival for using STEEP criteria Primary Outcome (Standardized Definitions for Efficacy End Points in adjuvant Measures breast cancer trials)

• Ribociclib + endocrine therapy Arms/Intervention • Endocrine therapy

Pre and postmenopausal women and men with HR-positive, Target Patients HER2-negative EBC, after adequate surgical resection, who are eligible for adjuvant endocrine therapy

Read-out Milestone(s) 2022 Publication TBD

107 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Kymriah® – CAR-T therapy

Study NCT03568461 ELARA (CCTL019E2202) NCT03876769 CASSIOPEIA (CCTL019G2201J) Indication Relapsed / refractory follicular lymphoma (FL) 1st line high risk acute lymphoblastic leukemia (ALL) Phase Phase 2 Phase 2 Patients 97 160

Primary Outcome Complete Response Rate (CRR) Disease Free Survival (DFS) Measures

Arms/Intervention Single-arm study of tisagenlecleucel Single-arm study of tisagenlecleucel Target Patients Adult patients with relapsed or refractory FL Pediatric and young adult patients with 1st line high risk ALL Read-out Milestone(s) H1-2021 2025

ELARA interim analysis presentation at ASH (American High-risk patients (ELIANA/CASSIOPEIA) – Planned Publication Society of Hematology) 2020. submission H1-2022

108 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Kymriah® – CAR-T therapy

Study NCT03570892 BELINDA (CCTL019H2301) Indication 2nd line Diffuse large B-cell lymphoma (DLBCL) Phase Phase 3 Patients 318

Primary Outcome Event-free Survival (EFS) Measures Arms/Intervention Tisagenlecleucel versus standard of care Adult patients with aggressive B-cell Non-Hodgkin Lymphoma Target Patients after failure of rituximab and anthracycline- containing frontline immunochemotherapy Read-out Milestone(s) H2-2021

• Bishop et al at SITC 2019 Publication • Abstract submission to congress in H2-2021

109 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation MBG453 – TIM-3 antagonist

Study NCT03946670 STIMULUS MDS-1 (CMBG453B12201) NCT04266301 STIMULUS-MDS2 (CMBG453B12301) Indication Myelodysplastic syndrome Myelodysplastic syndrome Phase Phase 2 Phase 3 Patients 120 500

Primary Outcome Complete Remission (CR) rate and Progression Free Survival Measures (PFS) Overall survival

• Experimental: Sabatolimab (MBG453) + hypomethylating • Sabatolimab 800 mg + azacitidine 75 mg/m2 Arms/Intervention agents • Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo • Placebo comparator: Placebo + hypomethylating agents Patients with intermediate, high or very high risk Adult subjects with intermediate, high or very high risk Target Patients Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelodysplastic Syndrome (MDS) as per IPSS-R criteria Myelomonocytic Leukemia-2 (CMML-2) Read-out Milestone(s) H2-2021 2023 Publication Abstract submission to congress in H2-2021 TBD

110 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation MBG453 – TIM-3 antagonist

Study NCT04150029 STIMULUS-AML1 (CMBG453C12201) Indication Acute Myeloid Leukemia (AML) Phase Phase 2 Patients 86 • Incidence of dose limiting toxicities (Safety run-in patients Primary Outcome only) Measures • Percentage of subjects achieving complete remission (CR) • Single arm safety and efficacy study of sabatolimab in Arms/Intervention combination with azacitidine and venetoclax

Newly diagnosed adult AML patients who are not suitable for Target Patients treatment with intensive chemotherapy

Read-out Milestone(s) 2024 Publication TBD

111 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation PDR001 – PD-1 checkpoint inhibitor

Study NCT03484923 (CPDR001J2201) Indication Previously treated unresectable or metastatic melanoma Phase Phase 2 Patients 195

Primary Outcome Objective Response Rate (ORR) Measures

• Spartalizumab (PDR001) 400mg i.v. Q4W + LAG525 (to be tested in unselected patients and LAG-3 positive patients) Arms/Intervention • Spartalizumab 400mg i.v. Q4W + capmatinib • Spartalizumab 400mg i.v. Q4W + canakinumab • Spartalizumab 400mg i.v. Q4W + ribociclib

Adult patients with previously treated unresectable or Target Patients metastatic melanoma

Read-out Milestone(s) 2022 Publication TBD

112 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Promacta®/Revolade® – Thrombopoietin receptor agonist

Study NCT03025698 (CETB115E2201) NCT03988608 (CETB115E2202)

Previously untreated or relapsed/refractory severe aplastic Previously untreated or relapsed/refractory severe aplastic Indication anemia or recurrent aplastic anemia anemia or recurrent aplastic anemia

Phase Phase 2 Phase 2 Patients 60 20

Primary Outcome PK of eltrombopag at steady state in pediatric patients with Hematologic response rate rate up to 26 weeks of treatment Measures SAA

• Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS • Arm A: relapsed/refractory SAA or recurrent AA following IST for SAA: hATG/cyclosporine + eltrombopag or Arms/Intervention • Eltrombopag 25 mg film-coated tablets cyclosporine + eltrombopag • Arm B: previously untreated SAA: hATG/cyclosporine + eltrombopag

Pediatric patients from age 1 <18 years with Chinese patients with refractory or relapsed severe aplastic Target Patients relapsed/refractory SAA or recurrent AA after IST or anemia previously untreated SAA

Read-out Milestone(s) Primary: 2025; Final: 2027 Primary: 2021; Final: 2023 Publication TBD TBD

113 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Rydapt® – Multi-targeted kinase inhibitor

Study NCT03280030 (CPKC412A2220) NCT03591510 (CPKC412A2218) Indication Acute myeloid leukemia Acute myeloid leukemia Phase Phase 2 Phase 2 Patients 66 50 Primary Outcome Occurrence of dose limiting toxicities Incidence of safety events and event free survival Measures Event Free Survival ( EFS)

• Midostaurin 50 mg Arms/Intervention • Chemotherapy followed by Midostaurin • Placebo

Newly diagnosed patients with FLT3-mutated acute myeloid Newly diagnosed pediatric patients with FLT3 mutated acute Target Patients leukemia (AML) from pan-Asia countries myeloid leukemia (AML)

Read-out Milestone(s) Interim: Q2-2020 (actual); Final: H2-2021 2022 Publication Abstract submission to congress in H2-2021 TBD

114 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation SEG101 – p-Selectin inhibitor

Study NCT03264989 SOLACE-Adults (CSEG101A2202) NCT03474965 SOLACE-Kids (CSEG101B2201) Prevention of Vaso-Occlusive Crises (VOC) in patients with Indication Prevention of VOC in pediatric patients with SCD Sickle Cell Disease (SCD) Phase Phase 2 Phase 2 Patients 57 100

Primary Outcome PK/PD and safety of SEG101 (crizanlizumab) at 5 mg/kg PK/PD and safety of SEG101 at 5 mg/kg Measures

SEG101 (crizanlizumab) at a dose of 5.0 mg/kg (or 7.5 mg/kg SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion ± Arms/Intervention for exploratory group) by IV infusion, ± Hydroxyurea/Hydroxycarbamide Hydroxyurea/Hydroxycarbamide

Target Patients Adult SCD patients with VOC Pediatric SCD patients with VOC H2-2021 (pediatric patients ≥12 year old) Read-out Milestone(s) 2019 (actual) 2024 (pediatric patients <12 year old)

Planned abstract submission to congress taking place in H2- Publication Liles D, et al. Presented at ASH 2020 2021

115 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation SEG101 – p-Selectin inhibitor

Study NCT03814746 STAND (CSEG101A2301)

Prevention of Vaso-Occlusive Crises (VOC) in patients with Indication Sickle Cell Disease (SCD)

Phase Phase 3

Patients 240

Primary Outcome Rate of VOC events leading to healthcare visit Measures

• Crizanlizumab 5.0 mg/kg Arms/Intervention • Crizanlizumab 7.5 mg/kg • Placebo Target Patients Adolescent and adult SCD patients (12 years and older) Read-out Milestone(s) 2022

Publication TBD

116 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Tafinlar® – BRAF inhibitor

Study NCT01677741 (CDRB436A2102) Indication BRAFV600 mutant cancers Phase Phase 1/2 Patients 85

Primary Outcome Safety, tolerability and pharmacokinetics Measures

Single-arm study of oral dabrafenib (dose based on age and Arms/Intervention weight)

Pediatric subjects aged 1 year to <18 years with advanced Target Patients BRAF V600-mutation positive solid tumors

Read-out Milestone(s) H1-2021 • Kieran MW et al. Clin Cancer Res 2019;25(24):7294-7302 (PK analysis) Publication • Hargrave DR et al. Clin Cancer Res 2019;25(24):7303-7311 (safety/efficacy in low-grade gliomas)

117 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Tafinlar®+Mekinist® – BRAF inhibitor and MEK inhibitor

Study NCT02684058 (CDRB436G2201) Indication BRAFV600 mutant gliomas Phase Phase 2 Patients 142

Primary Outcome Objective response rate Measures

Arms/Intervention Dabrafenib + trametinib (dose based on age and weight) Children and adolescent patients with BRAF V600 mutation Target Patients positive relapsed or refractory high grade glioma (HGG) or BRAF V600 mutation positive low grade glioma (LGG) Read-out Milestone(s) 2022

Publication TBD

118 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Tafinlar®+Mekinist® – BRAFV600 inhibitor and MEK inhibitor

Study NCT02124772 (CTMT212X2101) Indication BRAFV600 mutant solid tumors Phase Phase 1/2A Patients 139

Primary Outcome Safety, tolerability and pharmacokinetics and clinical activity Measures

Trametinib (dose based on age and weight) Arms/Intervention Dabrafenib + trametinib (dose based on age and weight)

Pediatric Subjects Aged 1 Month to <18 Years with Advanced Target Patients V600-Mutation Positive Solid Tumors

Read-out Milestone(s) H1-2021

• Geoerger B, et al. Presentation at ASCO 2020 Publication • Manuscript submission Q4-2020

119 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation 177Lu-PSMA-617 – Radioligand therapy targeting prostate specific membrane antigen (PSMA)

Study NCT03511664 VISION (PSMA-617-01)

PSMA-positive Metastatic Castration-resistant Prostate Indication Cancer (mCRPC)

Phase Phase 3 Patients 831

Primary Outcome • Radiographic Progression Free Survival Measures • Overall Survival

• 177Lu-PSMA-617 plus BS/BSC Arms/Intervention • BS/BSC alone

Adult patients with PSMA-positive Metastatic Castration- Target Patients resistant Prostate Cancer (mCRPC)

Read-out Milestone(s) H1-2021 Publication Abstract submission to congress in H2-2021

120 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Lutathera® – Radioligand therapy targeting somatostatin receptor type 2

Study NCT03972488 NETTER-2 (CAAA601A22301) Indication Gastroenteropancreatic neuroendocrine tumors (GEP-NET) Phase Phase 3 Patients 222

Primary Outcome • Progression Free Survival Measures

• Lutathera plus long-acting octreotide Arms/Intervention • high dose long-acting octreotide

Target Patients Adult patients with Grade 2 and Grade 3 Advanced GEP-NET Read-out Milestone(s) 2023 Publication TBD

121 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Ophthalmology Lucentis® – Anti-VEGF

Study NCT02640664 RAINBOW Extension (CRFB002H2301E1) Indication Retinopathy of Prematurity (ROP) Phase Phase 3 Patients 180

To evaluate the visual function of patients by assessing the Primary Outcome visual acuity in the better-seeing eye at the patient’s fifth Measures birthday.

• Ranibizumab 0.2 mg (up to Week 40, if warranted) Arms/Intervention • Ranibizumab 0.1 mg (up to Week 40, if warranted)

Male and female preterm infants with bilateral retinopathy of Target Patients prematurity (ROP) who completed RAINBOW. Read-out Milestone(s) 2023

Submission of publication of 2 year data (Interim Analysis 2) in Publication 2020

123 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Beovu® – Anti-VEGF

Study NCT02307682 HAWK (CRTH258A2301) NCT02434328 HARRIER (CRTH258A2302) Indication Neovascular age-related macular degeneration (nAMD) Neovascular age-related macular degeneration (nAMD) Phase Phase 3 Phase 3 Patients 1,082 743

Primary Outcome Change in Best Corrected Visual Acuity (BCVA) from baseline Change in Best Corrected Visual Acuity (BCVA) from baseline Measures at week 48 at week 48

• Brolucizumab (RTH258) 3 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Brolucizumab (RTH258) 6 mg/50 µL • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL Target Patients Subjects with exudative age-related macular degeneration Subjects with exudative age-related macular degeneration Read-out Milestone(s) 2018 (actual) 2018 (actual)

• Year 1 Manuscript: Dugel P, et al. Ophthalmology 2019 Apr 12; HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Publication • Year 2 Manuscript: Dugel P et al. Ophthalmology 2020 doi: 10.1016/j.ophtha.2020.06.028. [Epub ahead of print]

124 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Beovu® – Anti-VEGF

Study NCT04005352 TALON (CRTH258A2303) NCT03710564 MERLIN (CRTH258AUS04) Indication Neovascular Age-related Macular Degeneration (nAMD) Neovascular Age-related Macular Degeneration (nAMD) Phase Phase 3B Phase 3 Patients ~692 ~530 • Average change in Best-corrected visual acuity Primary Outcome • Distribution of the last interval with no disease activity (in a Change from baseline in Best-Corrected Visual Acuity (BCVA) Measures Treat-to-Control regimen)

Arm 1: Brolucizumab 6 mg intravitreal injection Arm 1: Brolucizumab 6 mg for intravitreal injection Arms/Intervention Arm 2: Aflibercept 2 mg intravitreal injection Arm 2: Aflibercept 2 mg for intravitreal injection

Patients with Neovascular Age-related Macular Degeneration Patients with Neovascular Age-related Macular Degeneration Target Patients (nAMD) who have not previously received anti-VEGF (nAMD) with persistent retinal fluid (vascular endothelial growth factor) treatment Read-out Milestone(s) 2022 H1-2021 Publication TBD TBD

125 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Beovu® – Anti-VEGF

Study NCT03386474 (CRTH258A2301E1) NCT03481634 KESTREL (CRTH258B2301) Indication Neovascular age-related macular degeneration (nAMD) Diabetic eye disease Phase Phase 3 Phase 3 Patients 150 534

Primary Outcome Number of treatment-emergent adverse events Change from baseline in best-corrected visual acuity (BCVA) Measures

• Brolucizumab (RTH258) 3 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Brolucizumab (RTH258) 6 mg/50 µL • Aflibercept 2 mg/50 µL • Aflibercept 2mg/50 uL

Patients with neovascular age-related macular degeneration Patients with visual impairment due to diabetic macular edema Target Patients who have completed the CRTH258A2301 study (DME)

Read-out Milestone(s) 2018 (actual) Primary: Q4-2020; Final: H2-2021 Week 52 safety and efficacy data of KITE1 and KESTREL Planned publication of the attributes of brolucizumab and studies combined in 1 abstract to be submitted to ARVO (May Publication durability in H1-2021 2021) with additional submissions planned to ASRS, Euretina, AAO

1. Kite Pharma, Inc. is neither a sponsor nor associated with Novartis’ KITE trial

126 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Beovu® – Anti-VEGF

Study NCT03481660 KITE (CRTH258B2302) NCT04058067 KINGLET (CRTH258B2304) Indication Diabetic eye disease Diabetic macular edema Phase Phase 3 Phase 3 Patients 356 268

Primary Outcome Change from baseline in best-corrected visual acuity (BCVA) Change in best-corrected visual acuity (BCVA) Measures

• Brolucizumab (RTH258) 6 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Patients with visual impairment due to diabetic macular edema Chinese patients with visual impairment due to diabetic Target Patients (DME) macular edema

Read-out Milestone(s) Primary: Q3-2020 (actual); Final: H2-2021 2023 Week 52 safety and efficacy data of KITE1 and KESTREL studies combined in 1 abstract to be submitted to ARVO (May Publication Publication planned for 2023 2021) with additional submissions planned to ASRS, Euretina, AAO

1. Kite Pharma, Inc. is neither a sponsor nor associated with Novartis’ KITE trial

127 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Beovu® – Anti-VEGF

Study NCT03917472 KINGFISHER (CRTH258B2305) NCT03802630 RAPTOR (CRTH258C2301) Indication Diabetic macular edema Retinal vein occlusion Phase Phase 3 Phase 3 Patients 500 500

Primary Outcome Change in best-corrected visual acuity (BCVA) from baseline Change from baseline in best-corrected visual acuity (BCVA) Measures up to week 52 at week 24

• Brolucizumab (RTH258) 6 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Adult patients with visual impairment due to macular edema Target Patients Patients with visual impairment due to diabetic macular edema secondary to branch retinal vein occlusion

Read-out Milestone(s) H2-2021 2023 Publication Publication submission planned for 2022 Publication submission planned for 2024

128 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Beovu® – Anti-VEGF

Study NCT03810313 RAVEN (CRTH258C2302) NCT04047472 HOBBY (CRTH258A2307) Indication Retinal vein occlusion Macular degeneration Phase Phase 3 Phase 3 Patients 750 494

Primary Outcome Change from baseline in best-corrected visual acuity (BCVA) Change from baseline in best-corrected visual acuity (BCVA) Measures at week 24 at week 48

• Brolucizumab (RTH258) 6 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Adult patients with visual impairment due to macular edema Chinese patients with neovascular age-related macular Target Patients secondary to central retinal vein occlusion degeneration

Read-out Milestone(s) 2023 2024 Publication TBD TBD

129 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Beovu® – Anti-VEGF

Study NCT04278417 (CRTH258D2301) Indication Diabetic retinopathy Phase Phase 3 Patients 706

Primary Outcome Change from Baseline in BCVA Measures • Arm 1: RTH258 (Brolucizumab) 6 mg3 x q6w loading injections, followed by q12w maintenance through week 90 Arms/Intervention • Arm 2: Panretinal photocoagulation laser initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed

Target Patients Patients with proliferative diabetic retinopathy

Read-out Milestone(s) 2023 Publication TBD

130 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation UNR844 – Disulfide bonds modulator

Study NCT03809611 (CUNR844A2203) Indication Presbyopia Phase Phase 2 Patients 124

Primary Outcome Change in binocular distance-corrected near visual acuity Measures (DNCVA) from baseline at month 3

• 1.5% solution UNR844-Cl Arms/Intervention • Placebo

Target Patients Patients with presbyopia Read-out Milestone(s) Q1-2020 (actual)

Publication • Oral presentation at AAOptom 2020

131 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation ECF843A – Lubrification / anti-inflammatory

Study NCT04391894 (CECF843A2201)

Indication Dry Eye Disease

Phase Phase 2

Patients 680 • Change from baseline in symptom assessment in Dry Primary Outcome Eye (SANDE) score Measures • Change from baseline in composite corneal fluorescein staining score A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects with dry eye disease Arms/Intervention ECF843 0.15 or 0.45 mg/mL BID/TID/vehicle

Target Patients Patients with moderate to severe dry eye disease (DED) Read-out Milestone(s) H2-2021

Publication tbd

132 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Respiratory INC424 – JAK Inhibitor

Study NCT04362137 RUXCOVID (CINC424J12301) Indication COVID-19 (cytokine storm) Phase Phase 3 Patients 402

Primary Outcome Proportion of patients who die, develop respiratory failure (requires Measures mechanical ventilation), or require intensive care unit care

• Ruxolitinib 5 mg tablet given bid Arms/Intervention • Placebo

Target Patients Patients with COVID-19 respiratory disease

Read-out Milestone(s) Dec 2020 (Actual) Publication • Manuscript submission planned for Q1-2021

134 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation QBW251 – CFTR potentiator

Study NCT04072887 (CQBW251B2201) Indication Chronic obstructive pulmonary disease (COPD) Phase Phase 2 Patients 956

Primary Outcome Trough FEV1 (Forced Expiratory Volume in 1 second) change Measures from baseline after 12 weeks of treatment • QBW251 450 mg • QBW251 300 mg • QBW251 150 mg Arms/Intervention • QBW251 75 mg • QBW251 25 mg • Placebo COPD patients on background triple inhaled therapy (LABA / Target Patients LAMA / ICS)

Read-out Milestone(s) H1-2022 Publication Manuscript submission planned for 2022

135 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation CSJ117 – TSLP inhibitor

Study NCT04410523 (CCSJ117A12201C) Indication Asthma Phase Phase 2 Patients 625 Pre-dose FEV1 (Forced Expiratory Volume in 1 second) Primary Outcome change from baseline after 12 weeks of treatment. Average Measures change from baseline in pre-dose FEV1 at week 8 & week 12

• CSJ117 0.5mg • CSJ117 1mg • CSJ117 2 mg Arms/Intervention • CSJ117 4 mg • CSJ117 8 mg • Placebo

Asthma patients on background medium or high ICS plus Target Patients LABA therapy

Read-out Milestone(s) 2022 Publication TBD

136 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation QVM149 – Long-acting beta2 agonist, Long-acting muscarinic antagonist and inhaled corticosteroid

Study NCT03100500 (CQVM149B1305) NCT03100825 (CQVM149B1304) Indication Asthma Asthma Phase Phase 3 Phase 3 Patients 51 94

Primary Outcome Long-term safety/tolerability: Incidence and severity of Long-term safety/tolerability: Incidence and severity of Measures treatment emergent adverse events during the 52 weeks study treatment emergent adverse events during the 52 weeks study

Arms/Intervention • Single arm: QMF149 150/320 μg od • Single Arm: QVM149 150/50/160 μg od Target Patients Japanese patients with asthma inadequately controlled Japanese patients with asthma inadequately controlled Read-out Milestone(s) 2019 (actual) 2019 (actual)

• Sagara H, et al. Abstract presented at ATS 2020 • Nakamura Y, et al. Abstract presented at ATS 2020 Publication • Planned publication in Q1-2021 • Planned publication in Q1-2021

137 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Sandoz Biopharmaceuticals Hyrimoz® – Biosimilar adalimumab

Study NCT02744755 ADMYRA (GP17-302) Indication Immunology Phase Phase 3 Patients 353 Change in DAS28-CRP score from baseline to week 12 in Primary Outcome patients treated with GP2017 and patients treated with Measures Humira®

• GP2017 Arms/Intervention • US licensed Humira® adalimumab

Target Patients Patients with moderate to severe active rheumatoid arthritis Read-out Milestone(s) 2018 (actual)

• Wiland, P. et al., presented at EULAR 2019 Publication • Wiland, P. et al., BioDrugs, Q2-2020

139 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation GP2411 – Biosimilar denosumab

Study NCT03974100 (CGP24112301) Indication Osteoporosis Phase Phase 3 Patients 522

Primary Outcome Percent change from baseline (%CfB) in lumbar spine Bone Measures Mineral Density

• GP2411 60 mg /mL subcutaneous injection every 6 months Arms/Intervention • Prolia® 60 mg /mL subcutaneous injection every 6 months

Target Patients Postmenopausal women with osteoporosis Read-out Milestone(s) 2022 Study data publications expected for 2024 and beyond. The Publication overall study design will be published at WCO and ECTS congresses 2020.

140 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Global Health KAF156 – Plasmodium Falciparum Inhibitor – PfCARL mediated

Study NCT03167242 (CKAF156A2202)

Indication Malaria

Phase Phase 2

Patients ~500

Primary Outcome PCR-corrected adequate clinical and parasitological response Measures (ACPR)

• KAF156 and LUM-SDF (different combinations) Arms/Intervention • Coartem

Adults and children with uncomplicated Plasmodium Target Patients Falciparum Malaria

Read-out Milestone(s) H2-2021

• Two posters accepted, ASTMH meeting Nov 15-19 2020 Publication • Kublin JG et al. Clinical Infectious Diseases 09 Jul 2020, PMID: 32644127

142 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation KAE609 – Plasmodium Falciparum Inhibitor – spiroindolone against PfATP4

Study NCT03334747 (CKAE609A2202) Indication Malaria Phase Phase 2 Patients 186

CTCAE grades increase from baseline in alanine aminotransferase (ALT) or aspartate Primary Outcome Measures aminotransferase (AST)

• KAE609 Arms/Intervention • Coartem

Target Patients Adults with uncomplicated Plasmodium Falciparum malaria Read-out Milestone(s) Q1-2020 (actual) • Poster accepted for ASTMH meeting Nov 15-19 2020 • Publication McCarthy JS et al. Antimicrobial agents and chemotherapy Journal. Published 20 Nov 2020. DOI: 10.1128/AAC.01423-20 • Bouwman SA, Zoleko-Manego R, Renner KC, Schmitt EK, Mombo-Ngoma, G, Grobusch MP, Publication The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound, Travel Medicine and Infectious Disease (2020), doi: https://doi.org/10.1016/ j.tmaid.2020.101765. • Further publications planned H1-2021

143 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation Abbreviations aBC Advanced breast cancer IPF Idiopathic pulmonary fibrosis AD Atopic Dermatitis mCRPC Metastatic castration-resistant prostate cancer AIH Autoimmune hepatitis MDR Multi-drug resistant aHUS atypical Hemolytic Uremic Syndrome MDS Myelodysplastic syndrome ALL Acute lymphoblastic leukemia MS Multiple sclerosis ALS Amyotrophic lateral sclerosis wAMD Wet (neovascular) age-related macular degeneration AMI Acute myocardial infarction NASH Non-alcoholic steatohepatitis AML Acute myeloid leukemia nHCM Non-obstructive hypertrophic cardiomyopathy AS H2H Ankylosing spondylitis head-to-head study versus adalimumab nr-axSpA Non-radiographic axial spondyloarthritis BC Breast cancer NSCLC Non-small cell lung cancer C3G C3 glomerulopathy PDR Proliferative diabetic retinopathy CCF Congestive cardiac failure PEF Preserved ejection fraction CLL Chronic lymphocytic leukemia PedPsO Pediatric psoriasis CML Chronic myeloid leukemia PNH Paroxysmal nocturnal haemoglobinuria CRC Colorectal cancer PsA H2H Psoriatic arthritis head-to-head study versus adalimumab COPD Chronic obstructive pulmonary disease RCC Renal cell carcinoma COSP Chronic ocular surface pain PROS PIK3CA related overgrowth spectrum CRSwNP Severe chronic rhinosinusitis with nasal polyps RA Rheumatoid arthritis CSU Chronic spontaneous urticaria rMS Relapsing multiple sclerosis CVRR-Lp(a) Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) ROP Retinopathy of prematurity CVRR-LDLC Secondary prevention of cardiovascular events in patients with elevated levels of LDLC RP Retinitis pigmentosa DME Diabetic macular edema RVO Retinal vein occlusion DLBCL Diffuse large B-cell lymphoma refractory SAA Severe aplastic anemia FL Follicular lymphoma SLE Systemic lupus erythematosus GCA Giant cell arteritis SMA Type 1 Spinal muscular atrophy (IV formulation) GVHD Graft-versus-host disease SMA Type 2/3 Spinal muscular atrophy (IT formulation) HCC Hepatocellular carcinoma SpA Spondyloarthritis HD Huntington’s disease SPMS Secondary progressive multiple sclerosis HFpEF Chronic heart failure with preserved ejection fraction TNBC Triple negative breast cancer HF-rEF Chronic heart failure with reduced ejection fraction T1DM Type 1 Diabetes mellitus HNSCC Head and neck squamous cell carcinoma HS Hidradenitis suppurativa IA Interim analysis IgAN IgA nephropathy iMN Membranous nephropathy

144 Novartis Q4 Results | January 26, 2021 | Novartis Investor Presentation